



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 July 2019
EMA/CHMP/378959/2019
Inspections, Human Medicines Pharmacovigilance and Committees Division

Committee for medicinal products for human use (CHMP)

Final Minutes for the meeting on 27-29 May 2019

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Disclaimers

Some of the information contained in the minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, the minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	7
1.1.	Welcome and declarations of interest of members, alternates and experts.....	7
1.2.	Adoption of agenda	7
1.3.	Adoption of the minutes	7
2.	Oral Explanations	7
2.1.	Pre-authorisation procedure oral explanations.....	7
2.1.1.	romosozumab - EMEA/H/C/004465.....	7
2.1.2.	angiotensin II - EMEA/H/C/004930	8
2.1.3.	ibalizumab - EMEA/H/C/004961.....	8
2.2.	Re-examination procedure oral explanations	8
2.2.1.	Doxolipad - doxorubicin hydrochloride - EMEA/H/C/004110	8
2.3.	Post-authorisation procedure oral explanations	9
2.4.	Referral procedure oral explanations	9
3.	Initial applications	9
3.1.	Initial applications; Opinions	9
3.1.1.	Cufence - trientine dihydrochloride - Orphan - EMEA/H/C/004111	9
3.1.2.	LysaKare - L-lysine hydrochloride / L-arginine hydrochloride - EMEA/H/C/004541.....	9
3.1.3.	Posaconazole Accord - posaconazole - EMEA/H/C/005005.....	10
3.1.4.	Posaconazole AHCL - posaconazole - EMEA/H/C/005028.....	10
3.1.5.	Xyndari - glutamine - Orphan - EMEA/H/C/004734	10
3.1.6.	Ultomiris - ravulizumab - Orphan - EMEA/H/C/004954	11
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	11
3.2.1.	dapagliflozin / saxagliptin / metformin hydrochloride - EMEA/H/C/004910	11
3.2.2.	deferasirox - EMEA/H/C/005014	11
3.2.3.	erlotinib - EMEA/H/C/005071	12
3.2.4.	romosozumab - EMEA/H/C/004465.....	12
3.2.5.	levodopa - EMEA/H/C/004786	12
3.2.6.	siponimod - EMEA/H/C/004712	12
3.2.7.	etanercept - EMEA/H/C/004711.....	13
3.2.8.	delafloxacin - EMEA/H/C/004860	13
3.2.9.	crisaborole - EMEA/H/C/004863	13
3.2.10.	tigecycline - EMEA/H/C/005114	14
3.2.11.	ibalizumab - EMEA/H/C/004961.....	14
3.2.12.	larotrectinib - Orphan - EMEA/H/C/004919	14
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	15

3.3.1.	azacitidine - EMEA/H/C/005147	15
3.3.2.	azacitidine - EMEA/H/C/005075	15
3.3.3.	cinacalcet - EMEA/H/C/005236	15
3.3.4.	diclofenamide - Orphan - EMEA/H/C/005141	15
3.3.5.	entrectinib - EMEA/H/C/004936	16
3.3.6.	alpelisib - EMEA/H/C/004804	16
3.3.7.	ivosidenib - Orphan - EMEA/H/C/005056	16
3.3.8.	upadacitinib - EMEA/H/C/004760	16
3.3.9.	cholera vaccine, oral, live - EMEA/H/C/003876	17
3.3.10.	gilteritinib - Orphan - EMEA/H/C/004752	17
3.4.	Update on on-going initial applications for Centralised procedure.....	17
3.4.1.	cannabidiol - Orphan - EMEA/H/C/004675	17
3.4.2.	enasidenib - Orphan - EMEA/H/C/004324	17
3.4.3.	imipenem / cilastatin / relebactam - EMEA/H/C/004808	18
3.4.4.	ciprofloxacin - EMEA/H/C/004394	18
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	18
3.5.1.	Doxolipad - doxorubicin hydrochloride - EMEA/H/C/004110	18
3.6.	Initial applications in the decision-making phase.....	19
3.6.1.	Nuceiva - botulinum toxin type a - EMEA/H/C/004587	19
3.7.	Withdrawals of initial marketing authorisation application	19
3.7.1.	Ambrisentan Zentiva - ambrisentan - EMEA/H/C/004955	19
3.7.2.	Radicava - edaravone - Orphan - EMEA/H/C/004938	19
3.7.3.	ABP 710 - infliximab - EMEA/H/C/005020	19
4.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	20
4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	20
4.1.1.	Nucala - mepolizumab - EMEA/H/C/003860/X/0018	20
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	20
4.2.1.	Tecentriq - atezolizumab - EMEA/H/C/004143/X/0017	20
4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	21
4.3.1.	Dificlir - fidaxomicin - EMEA/H/C/002087/X/0034/G	21
4.3.2.	Vyndaqel - tafamidis - Orphan - EMEA/H/C/002294/X/0049/G	21
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	22
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	22

5.	Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008	22
5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information	22
5.1.1.	Bavencio - avelumab - Orphan - EMEA/H/C/004338/II/0009/G	22
5.1.2.	Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0045	23
5.1.3.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0072	23
5.1.4.	Lucentis - ranibizumab - EMEA/H/C/000715/II/0074/G	23
5.1.5.	MabThera - rituximab - EMEA/H/C/000165/II/0162	24
5.1.6.	Revlimid - lenalidomide - Orphan - EMEA/H/C/000717/II/0107	24
5.1.7.	SIRTURO - bedaquiline - Orphan - EMEA/H/C/002614/II/0033/G	25
5.1.8.	Tecentriq - atezolizumab - EMEA/H/C/004143/II/0019	25
5.1.9.	Xyrem - sodium oxybate - EMEA/H/C/000593/II/0076	26
5.1.10.	Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0020	26
5.1.11.	WS1501 Anoro Ellipta - umeclidinium / vilanterol - EMEA/H/C/002751/WS1501/0024 Laventair Ellipta - umeclidinium / vilanterol - EMEA/H/C/003754/WS1501/0027	26
5.1.12.	WS1505 Incruse Ellipta - umeclidinium bromide - EMEA/H/C/002809/WS1505/0023 Rolufta Ellipta - umeclidinium - EMEA/H/C/004654/WS1505/0008	27
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	27
5.2.1.	WS1372 OPDIVO - nivolumab - EMEA/H/C/003985/WS1372/0053 Yervoy - ipilimumab - EMEA/H/C/002213/WS1372/0057	27
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	28
6.	Ancillary medicinal substances in medical devices	28
6.1.	Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions	28
6.2.	Update of Ancillary medicinal substances in medical devices	28
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	28
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	28
8.	Pre-submission issues	28
8.1.	Pre-submission issue	28
8.1.1.	givosiran - H0004775	28
8.2.	Priority Medicines (PRIME)	29
8.2.1.	List of applications received	29
8.2.2.	Recommendation for PRIME eligibility	29
9.	Post-authorisation issues	29
9.1.	Post-authorisation issues	29

9.1.1.	Fabrazyme - Agalsidase Beta - EMEA/H/C/000370/MEA 057.10	29
9.1.2.	Zalmoxis - nalotimagene carmaleucel - EMEA/H/C/002801/R/0015 - Orphan, ATMP.....	29
9.1.3.	Zalmoxis - nalotimagene carmaleucel - EMEA/H/C/002801/II/0016 - Orphan, ATMP	30
9.1.4.	RoActemra - tocilizumab - EMEA/H/C/000955	30
9.1.5.	Aflunov - pre-pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/002094/II/0044/G	30

10. Referral procedures 31

10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	31
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	31
10.2.1.	Direct Oral Anticoagulants (DOAC) - EMEA/H/A-5(3)/1478.....	31
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	31
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	31
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	31
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	32
10.6.1.	Methocarbamol/Paracetamol– EMEA/H/A-31/1484	32
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	32
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	32
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	32
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	33
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	33
10.11.1.	Basiron AC – benzoyl peroxide, hydrous – EMEA/H/A-13/1475	33

11. Pharmacovigilance issue 33

11.1.	Early Notification System	33
-------	--	-----------

12. Inspections 33

12.1.	GMP inspections	33
12.2.	GCP inspections	33
12.3.	Pharmacovigilance inspections.....	33
12.4.	GLP inspections	34

13. Innovation Task Force 34

13.1.	Minutes of Innovation Task Force.....	34
13.2.	Innovation Task Force briefing meetings.....	34
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	34
13.4.	Nanomedicines activities	34

14.	Organisational, regulatory and methodological matters	34
14.1.	Mandate and organisation of the CHMP	34
14.1.1.	Election CHMP Co-opted Member	34
14.2.	Coordination with EMA Scientific Committees	34
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	34
14.2.2.	Committee for Advanced Therapies (CAT)	35
14.2.3.	Committee for Herbal Medicinal Products (HMPC)	35
14.2.4.	Paediatric Committee (PDCO).....	35
14.2.5.	Committee for Orphan Medicinal Products (COMP)	35
14.2.6.	Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh).....	35
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	36
14.3.1.	Scientific Advice Working Party (SAWP)	36
14.3.2.	Biologics Working Party (BWP)	36
14.3.3.	Respiratory Drafting Group (RDG)	36
14.3.4.	Antimicrobial Advice ad hoc Expert Group (AMEG)	36
14.3.5.	Ad-hoc Influenza Working Group	37
14.4.	Cooperation within the EU regulatory network	37
14.5.	Cooperation with International Regulators	37
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	37
14.7.	CHMP work plan	37
14.8.	Planning and reporting	37
14.9.	Others	37
15.	Any other business	37
15.1.	AOB topic	37
16.	List of participants	37
17.	Explanatory notes	42

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See (current) May 2019 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 27-29 May 2019 (to be published post June 2019 CHMP meeting).

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 27-29 May 2019.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 23-26 April 2019.

ORGAM minutes for 20 May 2019.

The CHMP minutes for 23-26 April 2019 were adopted.

The Minutes of the May 2019 CHMP ORGAM meeting held on 20 May 2019, together with all decisions taken at that meeting, were adopted.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. romosozumab - EMEA/H/C/004465

treatment of osteoporosis

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 28 May 2019 at time 11:00

List of Outstanding Issues adopted on 28.02.2019, 15.11.2018, 20.09.2018. List of Questions adopted on 26.04.2018.

An oral explanation was held on Tuesday, 28 May 2019. The presentation mainly focused on efficacy and safety data.

See 3.2

2.1.2. [angiotensin II - EMEA/H/C/004930](#)

treatment of hypotension in adults with distributive or vasodilatory shock who remain hypotensive despite fluid and vasopressor therapy

Scope: Possible Oral explanation

Action: Oral explanation to be held on Tuesday, 28 May 2019 at time 09:00

List of Outstanding Issues adopted on 28.03.2019. List of Questions adopted on 18.10.2018.

The CHMP agreed that no oral explanation is needed this time.

2.1.3. [ibalizumab - EMEA/H/C/004961](#)

treatment of adults infected with HIV-1 resistant to at least 1 agent in 3 different classes

Scope: Possible Oral Explanation, SAG Report, list of outstanding issues

Action: Oral explanation to be held on Tuesday, 28 May 2019 at 14:00

List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 11.12.2018.

The CHMP noted the SAG report.

The CHMP agreed that no oral explanation is needed this time.

See 3.2

2.2. **Re-examination procedure oral explanations**

2.2.1. [Doxolipad - doxorubicin hydrochloride - EMEA/H/C/004110](#)

TLC Biopharmaceuticals B.V.; treatment of breast and ovarian cancer

Scope: Oral explanation, Draft list of experts for the ad hoc expert group meeting held on 20 May 2019 adopted via written procedure on 16 May 2019

Action: Oral explanation to be held on Monday, 27 May 2019 at time 14:00

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Opinion adopted on 31.01.2019. List of Outstanding Issues adopted on 26.07.2018. List of Questions adopted on 14.09.2017.

The CHMP noted the report from the ad-hoc expert group meeting and answers from PKWP.

An oral explanation was held on Monday, 27 May 2019. The presentation by the applicant focused mainly on the bioequivalence data.

See 3.5

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Cufence - trientine dihydrochloride - Orphan - EMEA/H/C/004111

Univar BV; treatment of Wilson's disease

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.03.2019, 31.01.2019. List of Questions adopted on 28.06.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.2. LysaKare - L-lysine hydrochloride / L-arginine hydrochloride - EMEA/H/C/004541

Advanced Accelerator Applications; reduction of renal radiation exposure during Peptide-Receptor Radionuclide Therapy (PRRT) with lutetium (¹⁷⁷Lu) oxodotreotide

Scope: Opinion

Action: For adoption

Well-established use application (Article 10a of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 28.03.2019. List of Questions adopted on 18.10.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.3. Posaconazole Accord - posaconazole - EMEA/H/C/005005

Accord Healthcare; treatment of fungal infections in adults

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Noxafil

List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 20.09.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.4. Posaconazole AHCL - posaconazole - EMEA/H/C/005028

Accord Healthcare; treatment of fungal infections in adults

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Noxafil

List of Outstanding Issues adopted on 28.03.2019. List of Questions adopted on 18.10.2018.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The CHMP noted the letter of recommendation dated 22 May 2019.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.5. Xyndari - glutamine - Orphan - EMEA/H/C/004734

Emmaus Medical Europe Ltd; treatment of sickle cell disease

Scope: Opinion

Action: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 31.01.2019. List of Questions adopted on 28.06.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The CHMP noted the two letters from the applicant.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation application. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal question and answers document was circulated for information.

3.1.6. Ultomiris - ravulizumab - Orphan - EMEA/H/C/004954

Alexion Europe SAS; treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Scope: Final opinion documents

Action: For information

New active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 26.04.2019, List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 15.11.2018.

The CHMP noted the final opinion documents.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. dapagliflozin / saxagliptin / metformin hydrochloride - EMEA/H/C/004910

- to improve glycaemic control when metformin with or without sulphonylurea (SU) does not provide adequate glycaemic control and where simultaneous addition of dapagliflozin and saxagliptin is considered necessary - to improve glycaemic control when metformin with or without sulphonylurea (SU) and either dapagliflozin or saxagliptin does not provide adequate glycaemic control - when already being treated with dapagliflozin and saxagliptin and metformin.

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.11.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.2. deferasirox - EMEA/H/C/005014

treatment of chronic iron overload

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 15.11.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

[3.2.3. erlotinib - EMEA/H/C/005071](#)

treatment of lung and pancreatic cancers

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 13.12.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

[3.2.4. romosozumab - EMEA/H/C/004465](#)

treatment of osteoporosis

Scope: Oral explanation

Action: Oral explanation to be held on Tuesday, 28 May 2019 at time 11:00

List of Outstanding Issues adopted on 28.02.2019, 15.11.2018, 20.09.2018. List of Questions adopted on 26.04.2018.

An oral explanation was held on Tuesday, 28 May 2019.

See 2.1

The Committee adopted a list of outstanding issues with a specific timetable.

[3.2.5. levodopa - EMEA/H/C/004786](#)

treatment of symptoms of OFF periods in Parkinson's disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.09.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

[3.2.6. siponimod - EMEA/H/C/004712](#)

treatment of secondary progressive multiple sclerosis (SPMS)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 31.01.2019.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. [etanercept - EMEA/H/C/004711](#)

Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, paediatric plaque psoriasis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.09.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. [delafloxacin - EMEA/H/C/004860](#)

treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in adults

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 20.09.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.9. [crisaborole - EMEA/H/C/004863](#)

treatment of mild to moderate atopic dermatitis

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 20.09.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues.

The CHMP agreed to the request by the applicant for a clock stop with a specific timetable.

3.2.10. tigecycline - EMEA/H/C/005114

treatment of soft tissue and intra-abdominal infections

- complicated skin and soft tissue infections, excluding diabetic foot infections

- complicated intra-abdominal infections

should be used only in situations where it is known or suspected that other alternatives are not suitable

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 13.12.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. ibalizumab - EMEA/H/C/004961

treatment of adults infected with HIV-1 resistant to at least 1 agent in 3 different classes

Scope: SAG Report, List of outstanding issues

Action: for adoption

List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 11.12.2018.

The CHMP noted the SAG report.

The CHMP agreed that no oral explanation is needed this time.

See 2.1

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.12. larotrectinib - Orphan - EMEA/H/C/004919

Bayer AG; treatment of adult and paediatric patients with locally advanced or metastatic solid tumours

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 28.03.2019. List of Questions adopted on 11.12.2018.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

The CHMP agreed to consult the BSWP. The list of questions will be adopted via written procedure.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. azacitidine - EMEA/H/C/005147

treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) and AML with >30% marrow blasts according to the WHO classification.

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the PKWP.

3.3.2. azacitidine - EMEA/H/C/005075

treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the PKWP.

3.3.3. cinacalcet - EMEA/H/C/005236

treatment of secondary hyperparathyroidism and hypercalcaemia

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. diclofenamide - Orphan - EMEA/H/C/005141

Sun Pharmaceutical Industries Europe B.V.; treatment of periodic paralysis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the

list of questions.

3.3.5. entrectinib - EMEA/H/C/004936

treatment of adult and paediatric patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive locally advanced or metastatic solid tumours and treatment of patients with ROS1-positive, advanced non-small cell lung cancer (NSCLC).

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. alpelisib - EMEA/H/C/004804

treatment of postmenopausal women, and men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an endocrine-based regimen

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. ivosidenib - Orphan - EMEA/H/C/005056

FGK Representative Service GmbH; treatment of adult patients (≥ 18 years old) with relapsed or refractory acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP agreed to consult the SAG Oncology and adopted a list of questions to this group.

The CHMP adopted the list of experts for the SAG Oncology meeting.

3.3.8. upadacitinib - EMEA/H/C/004760

treatment of moderate to severe active rheumatoid arthritis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. [cholera vaccine, oral, live - EMEA/H/C/003876](#)

indicated for active immunisation against disease caused by *Vibrio cholerae* serogroup O1 in adults and children aged 6 years and older

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. [gilteritinib - Orphan - EMEA/H/C/004752](#)

Accelerated assessment

Astellas Pharma Europe B.V.; treatment of patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. **Update on on-going initial applications for Centralised procedure**

3.4.1. [cannabidiol - Orphan - EMEA/H/C/004675](#)

GW Pharma (International) B.V.; Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS)

Scope: List of experts for the SAG Neurology meeting.

Action: For adoption

Oral Explanation held on 24.04.2019. List of Outstanding Issues adopted on 26.04.2019, 31.01.2019, 15.11.2018. List of Questions adopted on 31.05.2018.

The CHMP adopted the list of experts for the SAG Neurology meeting.

3.4.2. [enasidenib - Orphan - EMEA/H/C/004324](#)

Celgene Europe Limited; treatment of acute myeloid leukaemia (AML)

Scope: Letter from applicant dated 15 May 2019 requesting an extension of clock stop to respond to the list of outstanding issues adopted in April 2019.

List of experts for the SAG Oncology

Action: For adoption

List of Outstanding Issues adopted on 26.04.2019. List of Questions adopted on 18.10.2018.

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the list of outstanding issues adopted in April 2019.

The CHMP adopted the list of experts for the SAG Oncology meeting.

3.4.3. [imipenem / cilastatin / relebactam - EMEA/H/C/004808](#)

indicated for the treatment of bacterial infections due to gram-negative microorganisms

Scope: Letter from applicant dated 10 May 2019 requesting an extension of clock stop to respond to the list of questions adopted in March 2019.

Action: For adoption

List of Questions adopted on 28.03.2019.

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the list of questions adopted in March 2019.

3.4.4. [ciprofloxacin - EMEA/H/C/004394](#)

treatment of non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic lung infection with *Pseudomonas aeruginosa* (*P. aeruginosa*)

Scope: Letter from applicant dated 24 May 2019 requesting an extension of clock stop to respond to the list of outstanding issues adopted in March 2019.

Action: For adoption

List of outstanding issues adopted on 28.03.2019. List of Questions adopted on 26.07.2018.

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the list of outstanding issues adopted in March 2019.

3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004**

3.5.1. [Doxilipad - doxorubicin hydrochloride - EMEA/H/C/004110](#)

TLC Biopharmaceuticals B.V.; treatment of breast and ovarian cancer

Scope: Oral explanation, Draft list of experts for the ad hoc expert group meeting adopted via written procedure on 16 May 2019

Action: Oral explanation to be held on Monday, 27 May 2019 at time 14:00

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Opinion adopted on 31.01.2019. List of Outstanding Issues adopted on 26.07.2018. List of Questions adopted on 14.09.2017.

The CHMP noted the report from the ad-hoc expert group meeting and answers from PKWP. An oral explanation was held on Monday, 27 May 2019. The presentation by the applicant focused mainly on the bioequivalence data.

See 2.2

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation application. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal question and answers document was circulated for information.

3.6. Initial applications in the decision-making phase

3.6.1. Nuceiva - botulinum toxin type a - EMEA/H/C/004587

Evolus Pharma Limited; temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows

Scope: Request from the European Commission for clarification in relation to the Opinion adopted by the CHMP for Nuceiva at its April meeting.

Action: For information

Known active substance (Article 8(3) of Directive No 2001/83/EC)

Opinion adopted on 26.04.2019. List of Outstanding Issues adopted on 18.10.2018. List of Questions adopted on 09.11.2017.

The Committee discussed the request from the European Commission.

3.7. Withdrawals of initial marketing authorisation application

3.7.1. Ambrisentan Zentiva - ambrisentan - EMEA/H/C/004955

Zentiva, k.s.; treatment of pulmonary arterial hypertension (PAH)

Scope: Withdrawal of initial marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 31.01.2019. List of Questions adopted on 20.09.2018.

The CHMP noted the withdrawal of initial marketing authorisation application.

3.7.2. Radicava - edaravone - Orphan - EMEA/H/C/004938

Mitsubishi Tanabe Pharma GmbH; treatment of amyotrophic lateral sclerosis (ALS)

Scope: Withdrawal of initial marketing authorisation application

Action: For information

List of Outstanding Issues adopted on 28.02.2019. List of Questions adopted on 20.09.2018.

The CHMP noted the withdrawal of initial marketing authorisation application.

3.7.3. ABP 710 - infliximab - EMEA/H/C/005020

Amgen Europe B.V.; treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative colitis

Scope: Withdrawal of initial marketing authorisation application

Action: For information

The CHMP noted the withdrawal of initial marketing authorisation application.

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Nucala - mepolizumab - EMEA/H/C/003860/X/0018

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension application to introduce a new pharmaceutical form, solution for injection in pre-filled syringe or in pre-filled pen. The indication for this new pharmaceutical form is the same indication as the one approved for the lyophilised powder for solution for injection."

Action: For adoption

List of Questions adopted on 31.01.2019.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues

4.2.1. Tecentriq - atezolizumab - EMEA/H/C/004143/X/0017

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension application to add a new strength of 840 mg (60 mg/ml) for Tecentriq concentrate for solution for infusion in a vial and a new indication (metastatic triple-negative breast cancer (TNBC)). The new indication applies only to the 840 mg strength."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

List of Questions adopted on 31.01.2019.

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Dificlir - fidaxomicin - EMEA/H/C/002087/X/0034/G

Astellas Pharma Europe B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (40 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use of Dificlir in children from birth to less than 18 years of age.

The RMP (version 11.0) is updated in accordance.

Consequential updates have been made to the SmPC of Dificlir 200 mg Film-coated tablet.

The labelling and package leaflet (PL) are updated accordingly.

The PL is also being amended to include a statement that Dificlir is essentially 'sodium-free' (in accordance with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'). The details of the local representative of the MAH in the Czech Republic are also updated."

Action: For adoption

The Committee discussed the issues identified in this application. The discussion focused on missing comparability data between an earlier formulation and the intended marketed formulation. The members also discussed the paediatric clinical programme with specific focus on the safety data and whether an extrapolation from adults to the paediatric population was sufficiently justified. Other issues discussed were the need for an appropriate measuring device.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Vyndaqel - tafamidis - Orphan - EMEA/H/C/002294/X/0049/G

Pfizer Europe MA EEIG

Rapporteur: Joseph Emmerich, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension application to:

- introduce a new strength (tafamidis 61 mg soft capsules, pack-size of 30 and 90 capsules) including a new indication "treatment of transthyretin amyloidosis in adult patients with wild-type or hereditary cardiomyopathy to reduce all-cause mortality and cardiovascular-related hospitalisation (ATTR-CM)"

- introduce qualitative change; grouped with a type II variation (C.I.4) to update section 4.6 of the Vyndaqel (tafamidis meglumine) 20 mg soft capsules SmPC to add wording pertaining to the Tafamidis Enhanced Surveillance for Pregnancy Outcomes (TESPO) programme.

Submission of an updated RMP version 9.0 in order to include the proposed new dosage/indication, review of the additional data collected from the ATTR-CM clinical program and post marketing reporting, reclassify of the safety concerns, remove of HCP educational leaflet.

Relevant changes are proposed for Annex II.

In addition, the MAH is proposing an update to Section 16 Information in Braille of Annex IIIa - Labelling (carton) to differentiate between the dosage forms.”

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the bioequivalence of the new formulation, the target population with focus on patients with New York Heart Association class I and class III and the posology.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Bavencio - avelumab - Orphan - EMEA/H/C/004338/II/0009/G

Merck Europe B.V.

Rapporteur: Filip Josephson, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Anette Kirstine Stark

Scope: “Extension of indication to include a new indication for Bavencio as the first-line combination treatment with avelumab and axitinib in adult patients with advanced renal cell carcinoma; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing Authorisation Holder (MAH) takes the occasion to include changes in posology section 4.2 of the SmPC to support the switch of the avelumab dosing regimen from 10 mg/kg every two weeks (weight-based) to a flat dose of 800 mg every two weeks applicable to the new proposed indication aRCC and the already existing one (MCC). The MAH took the occasion to also implement some editorial changes in the product information. A proposed updated RMP has been submitted as well in version 1.7”

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning the efficacy data and the available data on the individual agent contribution to the combination treatment effect.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.2. [Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0045](#)

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include the adjuvant treatment of adult patients with HER2-positive early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Applicant took the opportunity to introduce editorial changes."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the safety data and the wording of the indication in accordance to the studied population. Furthermore the members discussed whether the request for an additional 1 year market protection was sufficiently justified.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. [Keytruda - pembrolizumab - EMEA/H/C/003820/II/0072](#)

Merck Sharp & Dohme B.V.

Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include a new indication for Keytruda as monotherapy for the treatment of recurrent locally advanced or metastatic oesophageal cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have received prior systemic therapy; as a consequence, sections 4.1, 4.2, and 5.1 of the SmPC, and section 1 of the PL are updated accordingly. The updated RMP version 25.1 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly relating to the efficacy data in the PD-L1 CPS ≥ 10 patient population and the wording of the indication with specific focus on the target population, taking into account patient data from different regions (EU and Asia).

The Committee adopted a request for supplementary information with a specific timetable.

5.1.4. [Lucentis - ranibizumab - EMEA/H/C/000715/II/0074/G](#)

Novartis Europharm Limited

Rapporteur: Kristina Dunder, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include new indication for Lucentis vial presentation: treatment of retinopathy of prematurity (ROP) in preterm infants; as a consequence, sections 2, 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet and

Labelling are updated in accordance. In addition, RMP version 18.0 is also submitted.
B.IV.1.a.1 – To introduce a low volume high accuracy syringe, as a stand-alone medical device for the administration of the Lucentis 0.2 mg paediatric dose (corresponding to 0.02 ml of the Lucentis 10 mg/ml solution for injection in vial presentations)."

Action: For adoption

Request for Supplementary Information adopted on 31.01.2019.

The Committee discussed the issues identified in this application, mainly focusing on visual outcome data and whether additional data can be generated post approval. The CHMP also discussed the proposed new medical device.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.5. [MabThera - rituximab - EMEA/H/C/000165/II/0162](#)

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include the treatment of paediatric patients (aged ≥ 2 to < 18 years old) with active polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA), for MA numbers EU/1/98/067/001-002 for MabThera; following efficacy and safety data from clinical study WA25615 (also known as Paediatric Polyangiitis and Rituximab Study [PePRS]) which was conducted to fulfil the measure of the Paediatric Investigational Plan (PIP: EMEA-000308-PIP02-11-M01) agreed upon in the context of rituximab development for treatment of adult patients with GPA and MPA (RAVE study). The CSR for Study 1: WA 25615 was submitted on 30th Oct 2018 as the Post Approval Measure submission according to Article 46 requirement. Linked to this variation the final compliance check procedure to close the PIP has started 3rd January 2019.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and sections 2, 3 and 4 of the Package Leaflet are updated accordingly. Furthermore, the PI is brought in line with the latest QRD template (version 10) and the opportunity is taken to combine the SmPC and PIL for 100mg and 500mg IV as they are identical except for strength specifications.

In addition, the applicant took the opportunity to implement minor editorial changes in the SmPC. The RMP version 20.0 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning the wording of the indication with regard to the maintenance setting and severity of disease as well as a possible extrapolation to children from 2-6 years of age.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. [Revlimid - lenalidomide - Orphan - EMEA/H/C/000717/II/0107](#)

Celgene Europe BV

Rapporteur: Alexandre Moreau, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Ghania Chamouni

Scope: "Extension of indication to include Revlimid in combination with rituximab (anti-CD20 antibody) for the treatment of adult patients with previously treated follicular lymphoma or

marginal zone lymphoma.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated; the PL is updated in accordance. An updated EU RMP (version 36.2) has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application, mainly concerning the wording of the indication with regard to the studied population as well as marginal zone lymphoma patients.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. [SIRTURO - bedaquiline - Orphan - EMEA/H/C/002614/II/0033/G](#)

Janssen-Cilag International NV

Rapporteur: Filip Josephson, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Grouping of an extension of indication to include patients 12 years of age and older for Sirturo and a Type II variation to change the safety information in Section 4.9 of the SmPC. The extension of indication is supported by the week 24 analysis of Cohort 1 (adolescent subjects aged ≥ 12 to < 18 years) of study TMC207-C211. Based on these data, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated version of the RMP (version 3.2) was included in the submission.”

Action: For adoption

Request for Supplementary Information adopted on 31.01.2019.

The Committee discussed the issues identified in this application, mainly relating to the extrapolation of safety and efficacy data from adults to adolescent patients.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.8. [Tecentriq - atezolizumab - EMEA/H/C/004143/II/0019](#)

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: “Extension of indication to include Tecentriq, in combination with nab-paclitaxel and carboplatin, indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. RMP version 9.0 has been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 31.01.2019.

The Committee discussed the issues identified in this application, mainly relating to the clinical data in relation to clinical practice.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.9. [Xyrem - sodium oxybate - EMEA/H/C/000593/II/0076](#)

UCB Pharma S.A.

Rapporteur: Bruno Sepodes, Co-Rapporteur: Mark Ainsworth, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include adolescents and children older than 7 years for Xyrem; As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. The updated version (9.0) of the RMP was submitted."

Action: For adoption

Request for Supplementary Information adopted on 15.11.2018.

The Committee discussed the issues identified in this application, mainly concerning the wording of the indication, the suitability of the dosing device for the lowest doses as well as the posology.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.10. [Zerbaxa - ceftolozane / tazobactam - EMEA/H/C/003772/II/0020](#)

Merck Sharp & Dohme B.V.

Rapporteur: Bjorg Bolstad, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Adam Przybylkowski

Scope: "Extension of indication to include treatment of nosocomial pneumonia, including ventilator associated pneumonia for Zerbaxa, based on results from the randomised, double-blind, multicentre clinical trial CXA-NP-11-04 (PN008).

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2, 5.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance (sections 1, 2, 3, 4 and 6).

The applicant also took the opportunity to implement editorial changes in section 5.2 of the SmPC and to bring section 4.4 of the SmPC and section 2 of the PL in line with the latest Annex to the EC guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. Version 2.1 of the RMP was also submitted."

Action: For adoption

Request for Supplementary Information adopted on 28.03.2019.

The Committee discussed the issues identified in this application, mainly concerning the wording of the indication.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.11. [WS1501](#) [Anoro Ellipta - umeclidinium / vilanterol - EMEA/H/C/002751/WS1501/0024](#) [Laventair Ellipta - umeclidinium / vilanterol - EMEA/H/C/003754/WS1501/0027](#)

GlaxoSmithKline (Ireland) Limited

Lead Rapporteur: Peter Kiely, Lead Co-Rapporteur: Ewa Balkowiec Iskra

Scope: "Update of sections 4.1. and 5.1 of the SmPC in order to update the efficacy information regarding the benefit on disease exacerbations of umeclidinium and

umeclidinium/vilanterol from the CTT116855 study (InforMing the PATHway of COPD Treatment [IMPACT]) and the benefit on disease exacerbations of vilanterol from the HZC113782 study (Study to Understand Mortality and Morbidity [SUMMIT]).
The Package Leaflet is updated in accordance.”

Action: For adoption

Request for Supplementary Information adopted on 31.01.2019.

The Committee discussed the issues identified in this application. The discussions mainly focused on the provided data on the effects of exacerbations.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. [WS1505](#) [Incruse Ellipta - umeclidinium bromide - EMEA/H/C/002809/WS1505/0023](#) [Rolufta Ellipta - umeclidinium - EMEA/H/C/004654/WS1505/0008](#)

GlaxoSmithKline (Ireland) Limited

Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead Co-Rapporteur: Peter Kiely

Scope: “Update of sections 4.1. and 5.1 of the SmPC in order to update the efficacy information regarding the benefit of umeclidinium and umeclidinium/vilanterol from the CTT116855 study (InforMing the PATHway of COPD Treatment [IMPACT]).
The Package Leaflet is updated in accordance.”

Action: For adoption

Request for Supplementary Information adopted on 31.01.2019.

The Committee discussed the issues identified in this application. The discussions mainly focused on the provided data on the effects of exacerbations.

The Committee adopted a request for supplementary information with a specific timetable.

5.2. [Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation \(EC\) No 1234/2008](#)

5.2.1. [WS1372](#) [OPDIVO - nivolumab - EMEA/H/C/003985/WS1372/0053](#) [Yervoy - ipilimumab - EMEA/H/C/002213/WS1372/0057](#)

Bristol-Myers Squibb Pharma EEIG

Lead Rapporteur: Jorge Camarero Jiménez, Lead Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: “Extension of indication to include first-line treatment of adult patients with metastatic Non-Small Cell Lung Carcinoma (NSCLC) for Opdivo and Yervoy; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information from the pivotal study CA209227 (an open-label, randomised phase 3 trial of nivolumab, or nivolumab plus ipilimumab, or nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in subjects with chemotherapy-naïve stage IV or recurrent NSCLC). The Package Leaflet and RMP (version 14.0 for Opdivo and version 21.0 for Yervoy) are updated in accordance. In addition, the MAH has taken the opportunity to introduce minor editorial and

formatting revisions in the PI.", Clockstop extension requested to respond to RSI.

Request by the applicant dated 24.05.2019 for an extension to the clock stop to respond to the RSI adopted on 13.12.2018.

Action: For adoption

Request for Supplementary Information adopted on 13.12.2018, 26.07.2018.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the RSI adopted on 13.12.2018 with a specific timetable.

5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

6. **Ancillary medicinal substances in medical devices**

6.1. **Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions**

No items

6.2. **Update of Ancillary medicinal substances in medical devices**

No items

7. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

7.1. **Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

No items

8. **Pre-submission issues**

8.1. **Pre-submission issue**

8.1.1. **givosiran - H0004775**

indicated for the treatment of acute hepatic porphyria in adults and adolescents

Scope: Briefing note and the rapporteurs' recommendation on the request for accelerated assessment

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Disclosure of information related to priority medicines cannot be released at present time as these contain commercially confidential information

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 5 recommendations for eligibility to PRIME: 1 was granted and 4 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Fabrazyme - Agalsidase Beta - EMEA/H/C/000370/MEA 057.10

Genzyme Europe BV; treatment of Fabry disease

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Outi Mäki-Ikola

Scope: Fabry registry - MAH's responses to the fifth biennial report (MEA 57.9) related to additional follow up of current and future patients treated with low dose regimens

Action: For discussion

The CHMP discussed the 5th biennial report of the Fabry registry.

9.1.2. Zalmoxis - nalotimagene carmaleucel - EMEA/H/C/002801/R/0015 - Orphan, ATMP

MolMed S.p.A

Rapporteur: Johannes Hendrikus Ovelgonne, Co-Rapporteur: Sol Ruiz, CHMP Coordinator of Rapporteur: Paula Boudewina van Hennik, CHMP Coordinator Co-Rapporteur: Maria Concepcion Prieto Yerro

Scope: Request for Supplementary Information

Action: For adoption

The CHMP was updated on discussions at the CAT at their May meeting.

The CHMP agreed to the request for supplementary information as adopted by the CAT with a specific timetable.

9.1.3. Zalmoxis - nalotimagene carmaleucel - EMEA/H/C/002801/II/0016 - Orphan, ATMP

MolMed S.p.A

Rapporteur: Johannes Hendrikus Ovelgonne, Co-Rapporteur: Sol Ruiz, CHMP Coordinator of Rapporteur: Paula Boudewina van Hennik, CHMP Coordinator Co-Rapporteur: Maria Concepcion Prieto Yerro

Scope: Request for Supplementary Information

"The MAH is proposing to terminate the study TK008 (specific obligation for the CMA) and replace it with study TK013"

Action: For adoption

The CHMP was updated on discussions at the CAT at their May meeting.

The CHMP agreed to the request for supplementary information as adopted by the CAT with a specific timetable.

9.1.4. RoActemra - tocilizumab - EMEA/H/C/000955

Roche Registration GmbH

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: Report for Roactemra LEG 055 which was reviewed by the PRAC during the May plenary, DHPC and communication plan intended to inform prescribers on the identified risk of hepatotoxicity associated with the use of RoActemra

Action: For adoption

The CHMP adopted the updated Assessment Report for the Post-Authorisation Measure LEG 055 including a request for update of SmPC and RMP. A DHPC was agreed to inform the prescribers of this new risk and should be disseminated as per the agreed communication plan.

9.1.5. Aflunov - pre-pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) - EMEA/H/C/002094/II/0044/G

Seqirus S.r.l

Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Amelia Cupelli

Scope: "Update of sections 4.4, 4.6, 4.8 and 5.1 of the SmPC following clinical study reports of studies V87_25 and V87_26 listed as post approval commitments; these are Phase 3, stratified, randomized, controlled, observer-blind, multicenter studies; the Package Leaflet and Labelling are updated accordingly. The updated RMP version 3.0 has also been submitted.

In addition, the marketing authorisation holder (MAH) took the opportunity to implement some amendments to the PI and make some additional minor editorial corrections."

Action: For adoption

Request for Supplementary Information adopted on 28.02.2019, 20.09.2018.

The members were updated on the procedure, in particular on concern related to low cross-protection with different strains for Aflunov.

The CHMP agreed to consult the VWP.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.2.1. Direct Oral Anticoagulants (DOAC) - EMEA/H/A-5(3)/1478

MAHs: various

Referral Rapporteur: Martina Weise, Referral Co-Rapporteurs: Kristina Dunder

Rapporteurs for involved CAPs:

Eliquis (APIXABAN):

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Nithyanandan Nagercoil;

Pradaxa (DABIGATRAN ETEXILATE):

Rapporteur: Mark Ainsworth, Co-Rapporteur: Joseph Emmerich;

Xarelto (RIVAROXABAN):

Rapporteur: Kristina Dunder, Co-Rapporteur: Martina Weise

Scope: List of outstanding issues

To assess the results of a non-interventional study regarding the risks of major bleeding in patients with non-valvular atrial fibrillation.

Action: For adoption

The CHMP agreed to consult the PRAC and adopted a list of questions to the Committee.

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

No items

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Methocarbamol/Paracetamol– EMEA/H/A-31/1484

FAES FARMA, S.A., DiaMed Beratungsgesellschaft fuer pharmazeutische Unternehmen mbH

Referral Rapporteur: Romaldas Maciulaitis, Referral Co-Rapporteur: Jorge Camarero Jimenez

Scope: Start of procedure, List of Questions, Timetable, Appointment of Rapporteurs

Action: For discussion

EMA received a notification from DE (BfArM) requesting the initiation of an Article 31 procedure for the fixed dose combination methocarbamol/paracetamol, based on concerns on efficacy (due to the dose of methocarbamol and role of paracetamol in the combination) and potential interactions between its active ingredients, which arose during the assessment of generic MAAs.

In the EU/EEA the combination is only authorised in Spain (since 1968), for use in the short-term, symptomatic treatment of painful muscle spasms associated with acute musculoskeletal disorders and generic MAAs referencing to the Spanish MA are currently under assessment in United Kingdom and Germany (as reference Member State).

The CHMP appointed Romaldas Maciulaitis as Rapporteur and Jorge Camarero Jimenez as Co-Rapporteur.

The CHMP adopted the procedure timetable.

List of questions: 29 May 2019

Submission of responses: 29.08.2019

Re-start of the procedure: 19.09.2019

Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 27.09.2019

Comments: 04.10.2019

Updated Rapporteur/co-rapporteur ARs circulated to CHMP: 10.10.2019

CHMP list of outstanding issues/CHMP opinion: October 2019 CHMP

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

No items

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

10.11.1. Basiron AC – benzoyl peroxide, hydrous – EMEA/H/A-13/1475

MAHs: Galderma Nordic AB

Re-examination Rapporteur: Romaldas Maciulaitis, Re-examination Co-Rapporteur: Alexandre Moreau

Initial Referral Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege

Scope: Request for withdrawal for re-examination

Action: For information

This procedure concerns a Type II Quality WS variation (SE/H/xxxx/WS/190). The notification received by the reference authority (SE) on 26/10/2018, notifying of the start of a referral under Article 13 of Commission regulation (EC) No 1234/2008.

Following the adoption of CHMP opinion in March 2019, the MAH submitted a request for re-examination. The CHMP noted that the MAH withdrew this request.

11. Pharmacovigilance issue

11.1. Early Notification System

May 2019 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

13.2. Innovation Task Force briefing meetings

Information related to briefing meetings taking place with applicants cannot be released at the present time as it is deemed to contain commercially confidential information

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Election CHMP Co-opted Member

Election of CHMP Co-opted Member with the area of expertise:

Expertise in biostatistics, principally on clinical trial methodology, and at least basic knowledge of the EU regulatory framework

Action: For election

The CHMP elected Christian Gartner (AT) as new CHMP co-opted member.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 13-16 May 2019

Action: For information

The CHMP noted the Summary of recommendations and advice.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for May 2019

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. [Committee for Advanced Therapies \(CAT\)](#)

CAT draft minutes of meeting held on 22-24 May 2019

Action: For information

The CHMP noted the draft minutes.

14.2.3. [Committee for Herbal Medicinal Products \(HMPC\)](#)

Report from the HMPC meeting held on 13-15 May 2019

Action: For information

The CHMP noted the report.

14.2.4. [Paediatric Committee \(PDCO\)](#)

PIPs reaching D30 at May 2019 PDCO

Action: For information

The CHMP noted the information.

Report from the PDCO meeting held on 27-29 May 2019

Action: For information

The CHMP noted the report.

14.2.5. [Committee for Orphan Medicinal Products \(COMP\)](#)

Report from the COMP meeting held on 21-23 May 2019

Action: For information

The CHMP noted the report.

14.2.6. [Coordination Group for Mutual Recognition and Decentralised Procedures – Human \(CMDh\)](#)

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 27-29 May 2019

Action: For information

The CHMP noted the report.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)

Chair: Anja Schiel

Report from the SAWP meeting held on 13-16 May 2019. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.2. Biologics Working Party (BWP)

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP 20-22 May 2019 meeting to CHMP for adoption:

- 16 reports on products in scientific advice and protocol assistance
- 4 reports on products in pre-authorisation procedures
- 4 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.3. Respiratory Drafting Group (RDG)

Chair: Karolina Toerneke

Scope: Respiratory drafting Group advice to PDCO on a PIP for Broncholitis Obliterans syndrome

Action: For discussion

The CHMP adopted the RDG advice.

14.3.4. Antimicrobial Advice ad hoc Expert Group (AMEG)

Scope:

Overview of comments received during the public consultation on the AMEG scientific advice on the preliminary risk profiling

Overview of comments received during the public consultation on the AMEG scientific advice on the categorisation of antimicrobials

Action: For information

The CHMP noted the overview of comments.

14.3.5. Ad-hoc Influenza Working Group

Scope:

Amended EU Strain selection for the Influenza Vaccines for the Season 2019/2020: Report from the Ad Hoc Influenza working group to the BWP

Amended EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2019/2020

Action: Adopted via written procedure on 15.05.2019

The CHMP noted the amended documents adopted via written procedure on 15 May 2019.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

No items

14.9. Others

No items

15. Any other business

15.1. AOB topic

No items

16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the May 2019 CHMP meeting

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Milena Stain	Alternate	Austria	No interests declared	
Bart Van der Schueren	Member	Belgium	No interests declared	
Mila Vlaskovska	Member	Bulgaria	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Loizos Panayi	Alternate	Cyprus	No interests declared	
Ondřej Slanař	Member	Czech Republic	No interests declared	
Tomas Boran	Alternate	Czech Republic	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Mark Ainsworth	Alternate	Denmark	No interests declared	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Alexandre Moreau	Member	France	No interests declared	
Joseph Emmerich	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Agnes Gyurasics	Member	Hungary	No interests declared	
Kolbeinn Gudmundsson	Member	Iceland	No interests declared	
Hrefna Gudmundsdottir	Alternate - via telephone*	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Daniela Melchiorri	Member	Italy	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Natalja Karpova	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on:	entrenectinib - EMEA/H/C/004936 Tecentriq - EMEA/H/C/004143/X/0017 Kadcyla - EMEA/H/C/002389/II/0045 MabThera - EMEA/H/C/000165/II/0162 Tecentriq - EMEA/H/C/004143/II/0019
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vic e-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No restrictions applicable to this meeting	
Simona Badoi	Member	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Rajko Kenda	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Jorge Camarero Jiménez	Alternate	Spain	No participation in final deliberations and voting on:	entrenectinib - EMEA/H/C/004936 Tecentriq - EMEA/H/C/004143/X/0017 Kadcyla - EMEA/H/C/002389/II/0045 MabThera - EMEA/H/C/000165/II/0162 Tecentriq - EMEA/H/C/004143/II/0019
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Greg Markey	Member	United Kingdom	No interests declared	
Koenraad Norga	Co-opted member	Belgium	No participation in final deliberations and voting on:	Nucala - EMEA/H/C/003860/X/0018 Anoro Ellipta - Laventair Ellipta - WS1501 Incruse Ellipta - Rolufta Ellipta - WS1505
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czech Republic	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Sabine Mayrhofer	Expert - in person*	Germany	No interests declared	
Anja Schiel	Expert - in person*	Norway	No interests declared	
Menno van der Elst	Expert - in person*	Netherlands	No interests declared	
Adrien Inoubli	Expert - via telephone*	France	No interests declared	
Eskild Colding-Jorgensen	Expert - via telephone*	Denmark	No restrictions applicable to this meeting	
Aldana Rosso	Expert - via telephone*	Denmark	No interests declared	
Lisbeth Bregnhøj	Expert - via telephone*	Denmark	No interests declared	
Agnieszka Przybyszewska	Expert - via telephone*	Ireland	No interests declared	
Sandra Bright	Expert - via telephone*	Ireland	No interests declared	
Ulla Wändel Liminga	Expert - via telephone*	Sweden	No interests declared	
Antoine Pariente	Expert - via telephone*	France	No restrictions applicable to meetings	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-Dol	Topics on agenda for which restrictions apply
Daniel Morales	Expert - via telephone*	UK	No interests declared	
Tove Lill Stendal	Expert - via telephone*	Norway	No interests declared	
Ingrid Lund	Expert - via telephone*	Norway	No interests declared	
Patrick Vrijlandt	Expert - via telephone*	Netherlands	No interests declared	
Caroline Auriche-Benichou	Expert - via telephone*	France	No interests declared	
Rune Kjekken	Expert - via telephone*	Norway	No restrictions applicable to this meeting	
Marion Haberkamp	Expert - via telephone*	Germany	No interests declared	
Blanca Garcia-Ochoa	Expert - via telephone*	Spain	No interests declared	
Elina Rönnemaa	Expert - via telephone*	Sweden	No interests declared	
Ahmad Nasiri	Expert - via telephone*	Sweden	No interests declared	
Aaron Emmanuel Sosa Mejia	Expert - via Adobe*	Denmark	No restrictions applicable to meetings	
Mette Linnert Jensen	Expert - via Adobe*	Denmark	No interests declared	
Christine Greiner	Expert - via Adobe*	Germany	No interests declared	
Henrike Potthast	Expert - via Adobe*	Germany	No interests declared	
Julian Paesler	Expert - via Adobe*	Germany	No interests declared	
Meeting run with the help of EMA staff				

*Experts were only evaluated against the product(s) they have been invited to talk about.

17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



19 July 2019
EMA/CHMP/387041/2019

Final Annex to 27-29 May 2019 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE SUBMISSION ISSUES	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	3
B.2.3. Renewals of Conditional Marketing Authorisations	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	7
B.4. EPARs / WPARs	12
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	14
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	15
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	19
B.5.3. CHMP-PRAC assessed procedures	33
B.5.4. PRAC assessed procedures.....	44
B.5.5. CHMP-CAT assessed procedures	53
B.5.6. CHMP-PRAC-CAT assessed procedures	53
B.5.7. PRAC assessed ATMP procedures	54
B.5.8. Unclassified procedures and worksharing procedures of type I variations.....	54
B.5.9. Information on withdrawn type II variation / WS procedure	56
B.5.10. Information on type II variation / WS procedure with revised timetable.....	58
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	58
B.6.1. Start of procedure for New Applications: timetables for information	58
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	60
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information	60



B.6.4. Annual Re-assessments: timetables for adoption	62
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	63
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	64
B.6.7. Type II Variations scope of the Variations: Extension of indication	64
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	66
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects	68
B.6.10. CHMP-PRAC assessed procedures.....	77
B.6.11. PRAC assessed procedures	80
B.6.12. CHMP-CAT assessed procedures	82
B.6.13. CHMP-PRAC-CAT assessed procedures.....	82
B.6.14. PRAC assessed ATMP procedures	82
B.6.15. Unclassified procedures and worksharing procedures of type I variations	83
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	86
B.7.1. Yearly Line listing for Type I and II variations.....	86
B.7.2. Monthly Line listing for Type I variations.....	86
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	86
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)	86
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)	86
B.7.6. Notifications of Type I Variations (MMD only)	86
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	86
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	86
E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES	86
E.1. PMF Certification Dossiers:	87
E.1.1. Annual Update.....	87
E.1.2. Variations:	87
E.1.3. Initial PMF Certification:	87
E.2. Time Tables – starting & ongoing procedures: For information	87
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	87
F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended	87
F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health.....	87
G. ANNEX G	87
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	87
G.2. Ongoing procedures	87
G.3. PRIME.....	87
G.3.1. List of procedures concluding at 26-29 May 2019 CHMP plenary:.....	87
G.3.2. List of procedures starting in May 2019 for June 2019 CHMP adoption of outcomes	88

H. ANNEX H - Product Shared Mailboxes – e-mail address88

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for Adopted.
May 2019: **For adoption**

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for Adopted.
May 2019: **For adoption**

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

Abasaglar - insulin glargine - EMA/H/C/002835/R/0023

Eli Lilly Nederland B.V., Rapporteur: Kristina
Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC
Rapporteur: Amelia Cupelli

Request for Supplementary Information adopted
on 28.03.2019.

Positive Opinion adopted by consensus together
with the CHMP assessment report and translation
timetable.

Based on the review of the available information,
the CHMP was of the opinion that the renewal of
the marketing authorisation can be granted with
unlimited validity.

The Icelandic and Norwegian CHMP Members
were in agreement with the CHMP Opinion.

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMA/H/C/001206/R/0062

GlaxoSmithKline Biologicals SA, Informed
Consent of Pandemrix (EXP), Rapporteur: Johann
Lodewijk Hillege, Co-Rapporteur: Jan
Mueller-Berghaus, PRAC Rapporteur: Menno van
der Elst

Request for Supplementary Information adopted

Positive Opinion adopted by consensus together
with the CHMP assessment report and translation
timetable.

Based on the review of the available information,
the CHMP was of the opinion that the renewal of
the marketing authorisation can be granted with
unlimited validity.

The Icelandic and Norwegian CHMP Members

on 26.04.2019.	were in agreement with the CHMP Opinion.
<p>Brimica Genuair - aclidinium / formoterol fumarate dihydrate - EMEA/H/C/003969/R/0026</p> <p>AstraZeneca AB, Duplicate, Duplicate of Duaklir Genuair, Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Adam Przybylkowski</p> <p>Request for Supplementary Information adopted on 29.05.2019.</p>	Request for supplementary information adopted with a specific timetable.
<p>Cyramza - ramucirumab - EMEA/H/C/002829/R/0031</p> <p>Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Kolbeinn Gudmundsson (IS) (MNAT with IS for Clinical Efficacy, IS for Coordination, IS for Clinical Safety, FI for Non-Clinical, FI for Quality, LT for Clinical Pharmacology), PRAC Rapporteur: Brigitte Keller-Stanislawski</p> <p>Request for Supplementary Information adopted on 29.05.2019.</p>	Request for supplementary information adopted with a specific timetable.
<p>Duaklir Genuair - aclidinium / formoterol fumarate dihydrate - EMEA/H/C/003745/R/0026</p> <p>AstraZeneca AB, Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Adam Przybylkowski</p> <p>Request for Supplementary Information adopted on 29.05.2019.</p>	Request for supplementary information adopted with a specific timetable.
<p>Duloxetine Lilly - duloxetine - EMEA/H/C/004000/R/0015</p> <p>Eli Lilly Nederland B.V., Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Maria del Pilar Rayon</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Harvoni - ledipasvir / sofosbuvir - EMEA/H/C/003850/R/0080</p> <p>Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Ana Sofia Diniz Martins</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members</p>

	were in agreement with the CHMP Opinion.
<p>Ketoconazole HRA - ketoconazole - EMEA/H/C/003906/R/0014, Orphan Laboratoire HRA Pharma, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Željana Margan Koletić</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Lymphoseek - tilmanocept - EMEA/H/C/002085/R/0016 Norgine B.V., Rapporteur: Jayne Crowe, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene Request for Supplementary Information adopted on 29.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Moventig - naloxegol - EMEA/H/C/002810/R/0028 Kyowa Kirin Holdings B.V., Rapporteur: Bart Van der Schueren, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ronan Grimes Request for Supplementary Information adopted on 29.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>MULTAQ - dronedarone - EMEA/H/C/001043/R/0042 sanofi-aventis groupe, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 29.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>OFEV - nintedanib - EMEA/H/C/003821/R/0025, Orphan Boehringer Ingelheim International GmbH, Rapporteur: Peter Kiely, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce Request for Supplementary Information adopted on 29.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Rezolsta - darunavir / cobicistat - EMEA/H/C/002819/R/0031 Janssen-Cilag International NV, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Amelia Cupelli</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with</p>

	<p>unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Tadalafil Mylan - tadalafil - EMEA/H/C/003787/R/0014 Mylan S.A.S, Generic, Generic of Cialis, Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Maria del Pilar Rayon</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>VIZAMYL - flutemetamol (18F) - EMEA/H/C/002557/R/0017 GE Healthcare AS, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber Request for Supplementary Information adopted on 28.03.2019.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>

B.2.3. Renewals of Conditional Marketing Authorisations

<p>Translarna - ataluren - EMEA/H/C/002720/R/0051, Orphan PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Liana Gross-Martirosyan Request for Supplementary Information adopted on 26.04.2019.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p>Zalmoxis - nalotimagene carmaleucel - EMEA/H/C/002801/R/0015, Orphan, ATMP MolMed S.p.A, Rapporteur: Carla Herbets, Co-Rapporteur: Sol Ruiz, CHMP Coordinators: Paula Boudewina van Hennik and Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted on 24.05.2019.</p>	<p>See agenda 9.1</p> <p>Request for supplementary information adopted with a specific timetable.</p>

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 13-16 May 2019 PRAC:

Signal of persistent sexual dysfunction after drug withdrawal Adopted.

Serotonin and noradrenaline reuptake inhibitors (SNRI); Selective serotonin reuptake inhibitors (SSRI); Vortioxetine – CYMBALTA; DULOXETINE LILLY; DULOXETINE MYLAN; DULOXETINE ZENTIVA; XERISTAR; YENTREVE (CAP & NAP)

PRAC recommendation on a variation: **For adoption**

Signal of interaction with boosted antiviral human immunodeficiency virus (HIV) therapy leading to insufficient inhibition of platelet aggregation Adopted.

Clopidogrel; clopidogrel/acetylsalicylic acid; Lopinavir, ritonavir; ritonavir - CLOPIDOGREL APOTEX, CLOPIDOGREL BGR, CLOPIDOGREL HCS, CLOPIDOGREL KRKA, CLOPIDOGREL KRKA D.D., CLOPIDOGREL MYLAN, CLOPIDOGREL RATIOPHARM, CLOPIDOGREL RATIOPHARM GMBH, CLOPIDOGREL TAD, CLOPIDOGREL TEVA, CLOPIDOGREL ZENTIVA, GREPID, ISCOVER, PLAVIX, ZYLLT; CLOPIDOGREL/ACETYLSALICYLIC ACID ZENTIVA, DUOPLAVIN, KALETRA, LOPINAVIR/RITONAVIR MYLAN, NORVIR, RITONAVIR (CAP & NAP)

PRAC recommendation on a variation: **For adoption**

Signal of colitis microscopic Adopted.

Pantoprazole – CONTROLOC CONTROL, PANTOLOC CONTROL, PANTOZOL CONTROL, SOMAC CONTROL (CAP & NAP)

PRAC recommendation on a variation: **For adoption**

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its May 2019 meeting:

EMA/H/C/PSUSA/00000060/201809 (adefovir) The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the

CAPS:

Hepsera (EMA/H/C/000485) (adefovir dipivoxil), Gilead Sciences Ireland UC, Rapporteur: Joseph Emmerich, PRAC Rapporteur: Adrien Inoubli, "Period Covered From: 21/09/2015 To: 20/09/2018"

PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to combine the wording of the two adverse drug reactions "proximal renal tubulopathy" and "Fanconi syndrome" to one adverse drug reaction "Proximal renal tubulopathy (including Fanconi syndrome)" with a change in frequency from 'unknown' to 'uncommon'. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/0000547/201810

(carbidopa / entacapone / levodopa)

CAPS:

Corbilta (EMA/H/C/002785) (levodopa / carbidopa / entacapone), Orion Corporation, Rapporteur: Outi Mäki-Ikola

Levodopa/Carbidopa/Entacapone Orion

(EMA/H/C/002441) (levodopa / carbidopa / entacapone), Orion Corporation, Rapporteur: Outi Mäki-Ikola

Stalevo (EMA/H/C/000511) (levodopa / carbidopa / entacapone), Orion Corporation, Rapporteur: Outi Mäki-Ikola

NAPS:

LEVODOPA/CARBIDOPA/ENTACAPONE

TORRENT - TORRENT PHARMA (UK) LTD, PRAC Rapporteur: Kirsti Villikka, "18 Oct 2015 TO 17 Oct 2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add Dopamine Dysregulation Syndrome (DDS) with a frequency "not known" and add further explanation with regards to DDS to section 4.8 to increase awareness and understanding on the pathology and add a warning to section 4.4 to recommend relevant precautions. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/0000939/201810

(deferasirox)

CAPS:

EXJADE (EMA/H/C/000670) (deferasirox), Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "01/11/2017 to 31/10/2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.2, 4.4 and 4.9 of the SmPC

to modify posology recommendations and an existing warning related to over-chelation and to modify information on overdose, respectively. The Package leaflet and the Guide for healthcare professionals in the Annex II are updated accordingly in relation to overdose and over-chelation, respectively.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00002919/201810

(thalidomide)

CAPS:

Thalidomide Celgene (EMA/H/C/000823) (thalidomide), Celgene Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, "10 October 2017 - 09 October 2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.2, 4.4 and 4.8 of the SmPC to add a warning and recommendations regarding the risk of severe skin reactions including DRESS and to add the adverse reaction DRESS with a frequency "not known". The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00003010/201809

(trastuzumab)

CAPS:

Herceptin (EMA/H/C/000278) (trastuzumab), Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus

Herzuma (EMA/H/C/002575) (trastuzumab), Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus

KANJINTI (EMA/H/C/004361) (trastuzumab), Amgen Europe B.V., BREDA, Rapporteur: Jan Mueller-Berghaus

Ontruzant (EMA/H/C/004323) (trastuzumab), Samsung Bioepis NL B.V., Rapporteur: Koenraad Norga

Trazimera (EMA/H/C/004463) (trastuzumab), Pfizer Europe MA EEIG, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, "08 Nov 2017 to 24 Sep 2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to include tumour lysis syndrome with a frequency Not known. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00010029/201810

The CHMP, having considered in accordance with

(dapagliflozin)

CAPS:

Edistride (EMA/H/C/004161) (dapagliflozin), AstraZeneca AB, Rapporteur: Kristina Dunder
Forxiga (EMA/H/C/002322) (dapagliflozin), AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "05 October 2017 to 04 October 2018"

Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisations for the above mentioned medicinal products, concerning the following change:

Update of section 4.8 of the SmPC to add the adverse reaction 'angioedema' with a frequency 'very rare'. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00010213/201810

(delamanid)

CAPS:

Deltyba (EMA/H/C/002552) (delamanid), Otsuka Novel Products GmbH, Rapporteur: Greg Markey, PRAC Rapporteur: Jean-Michel Dogné, "Period Covered From: 28/04/2018 To: 27/10/2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to add bedaquiline to the list of concomitant drugs known to prolong the QTc interval. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00010306/201810

(sofosbuvir / ledipasvir)

CAPS:

Harvoni (EMA/H/C/003850) (ledipasvir / sofosbuvir), Gilead Sciences Ireland UC, Rapporteur: Filip Josephson, PRAC Rapporteur: Ana Sofia Diniz Martins, "Period Covered From: 10/10/2017 To: 09/10/2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section Section 4.5 of the SmPC to add new information on the impact of direct-acting antiviral (DAA) therapy on drugs metabolized by the liver (e.g. immunosuppressive agents) and on the potential need for dose adjustment of those drugs when they are co-administered with DAA therapy. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned

recommendation of the CHMP.

EMA/H/C/PSUSA/00010318/201810

(nintedanib (oncology indications))

CAPS:

Vargatef (EMA/H/C/002569) (nintedanib),
Boehringer Ingelheim International GmbH,
Rapporteur: Sinan B. Sarac, PRAC Rapporteur:
Agni Kapou, "Period Covered From: 15/10/2017
To: 15/10/2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to include 'pulmonary embolism' in the section about venous thromboembolism and 'colitis' in section 4.8 of the SmPC with a not known frequency. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00010319/201810

(nintedanib (respiratory indication))

CAPS:

OFEV (EMA/H/C/003821) (nintedanib),
Boehringer Ingelheim International GmbH,
Rapporteur: Peter Kiely, PRAC Rapporteur: Nikica
Mirošević Skvrce, "Period Covered From:
15/10/2017 To: 15/10/2018"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction 'colitis' with a frequency 'uncommon'. The Package leaflet is updated accordingly.

The next PSUR should be submitted in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. MAH requested that the frequency of PSUR submission should be revised to 3 years. After the assessment of the PSUR, it is concluded that frequency of the PSUR will remain unchanged at the moment due to the identified safety concerns.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMA/H/C/PSUSA/00010449/201811

(cobicistat / elvitegravir / emtricitabine /
tenofovir alafenamide)

CAPS:

Genvoya (EMA/H/C/004042) (elvitegravir /

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the

cobicistat / emtricitabine / tenofovir alafenamide), Gilead Sciences Ireland UC, Rapporteur: Greg Markey, PRAC Rapporteur: Amelia Cupelli, "From: 04/11/2017 To: 04/11/2018"

terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add suicidal ideation and suicide attempt (in patients with a pre-existing history of depression or psychiatric illness) with frequency "uncommon". The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

B.4. EPARs / WPARs

ABP 710 (WD) - infliximab - EMEA/H/C/005020

Amgen Europe B.V., treatment of rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, psoriasis and ulcerative colitis, Similar biological application (Article 10(4) of Directive No 2001/83/EC)

WPAR

For information only. Comments can be sent to the PL in case necessary.

Ambrisentan Mylan - ambrisentan - EMEA/H/C/004985

Mylan S.A.S, treatment of pulmonary arterial hypertension (PAH), Generic, Generic of Volibris, Generic application (Article 10(1) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Ambrisentan Zentiva - ambrisentan - EMEA/H/C/004955

Zentiva, k.s., treatment of pulmonary arterial hypertension (PAH), Generic, Generic of Volibris, Generic application (Article 10(1) of Directive No 2001/83/EC)

WPAR

For information only. Comments can be sent to the PL in case necessary.

Cabazitaxel Teva - cabazitaxel - EMEA/H/C/004951

Teva B.V., treatment of prostate cancer, Hybrid application (Article 10(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Doptelet - avatrombopag - EMEA/H/C/004722

Dova Pharmaceuticals Ireland Limited, treatment of thrombocytopenia, New active substance (Article 8(3) of Directive No 2001/83/EC)

For information only. Comments can be sent to the PL in case necessary.

Dovato - dolutegravir / lamivudine - EMEA/H/C/004909

For information only. Comments can be sent to

ViiV Healthcare B.V., treatment of Human Immunodeficiency Virus type 1 (HIV-1), Fixed combination application (Article 10b of Directive No 2001/83/EC)	the PL in case necessary.
Esperoct - turoctocog alfa pegol - EMEA/H/C/004883, Orphan Novo Nordisk A/S, Treatment and prophylaxis of bleeding in patients with haemophilia A, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Grasustek - pegfilgrastim - EMEA/H/C/004556 Juta Pharma GmbH, reduction in the duration of neutropenia and the incidence of febrile neutropenia, Similar biological application (Article 10(4) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
LIBTAYO - cemiplimab - EMEA/H/C/004844 Regeneron Ireland U.C., as monotherapy, indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Nuceiva - botulinum toxin type a - EMEA/H/C/004587 Evolus Pharma Limited, temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Radicava (WD) - edaravone - EMEA/H/C/004938, Orphan Mitsubishi Tanabe Pharma GmbH, treatment of amyotrophic lateral sclerosis (ALS), New active substance (Article 8(3) of Directive No 2001/83/EC) WPAR	For information only. Comments can be sent to the PL in case necessary.
Sixmo - buprenorphine - EMEA/H/C/004743 L. Molteni & C. dei Fratelli Alitti Societa di Esercizio S.p.A., Substitution treatment for opioid drug dependence, Known active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
Striascan - ioflupane (123i) - EMEA/H/C/004745 CIS BIO International, indicated for detecting loss of functional dopaminergic neuron terminals in the striatum, Generic, Generic of DaTSCAN,	For information only. Comments can be sent to the PL in case necessary.

Generic application (Article 10(1) of Directive No 2001/83/EC)

Talzenna - talazoparib - EMEA/H/C/004674 For information only. Comments can be sent to the PL in case necessary.
Pfizer Europe MA EEIG, treatment of adult patients with germline breast cancer susceptibility gene (BRCA) mutated human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer, New active substance (Article 8(3) of Directive No 2001/83/EC)

Temybric Ellipta - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/005254 For information only. Comments can be sent to the PL in case necessary.
GlaxoSmithKline Trading Services, treatment of adult patients with chronic obstructive pulmonary disease (COPD), Informed Consent of Trelegy Ellipta, Informed consent application (Article 10c of Directive No 2001/83/EC)

Ultomiris - ravulizumab - EMEA/H/C/004954, Orphan For information only. Comments can be sent to the PL in case necessary.
Alexion Europe SAS, treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), New active substance (Article 8(3) of Directive No 2001/83/EC)

Xromi - hydroxycarbamide - EMEA/H/C/004837 For information only. Comments can be sent to the PL in case necessary.
Nova Laboratories Ireland Limited, prevention of complications of Sickle Cell disease, Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Zynteglo - autologous cd34+ cell enriched population that contains hematopoietic stem cells transduced with lentiglobin bb305 lentiviral vector encoding the beta-a-t87q-globin gene - EMEA/H/C/003691, Orphan, ATMP For information only. Comments can be sent to the PL in case necessary.
bluebird bio (Netherlands) B.V, treatment of transfusion-dependent β -thalassaemia (TDT), New active substance (Article 8(3) of Directive No 2001/83/EC)

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

Aimovig - erenumab - EMA/H/C/004447/II/0003/G Novartis Europharm Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 29.05.2019, 28.03.2019.	Request for supplementary information adopted with a specific timetable.
BeneFIX - nonacog alfa - EMA/H/C/000139/II/0156/G Pfizer Europe MA EEIG, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.05.2019. Request for Supplementary Information adopted on 28.03.2019.	Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Benepali - etanercept - EMA/H/C/004007/II/0042/G Samsung Bioepis NL B.V., Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 02.05.2019.	Request for supplementary information adopted with a specific timetable.
Busilvex - busulfan - EMA/H/C/000472/II/0030/G Pierre Fabre Medicament, Rapporteur: Jorge Camarero Jiménez Request for Supplementary Information adopted on 02.05.2019.	Request for supplementary information adopted with a specific timetable.
Evicel - human fibrinogen / human thrombin - EMA/H/C/000898/II/0067 Omrix Biopharmaceuticals N. V., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 02.05.2019.	Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Flixabi - infliximab - EMA/H/C/004020/II/0038 Samsung Bioepis NL B.V., Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 02.05.2019, 14.03.2019.	Request for supplementary information adopted with a specific timetable.
Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMA/H/C/004814/II/0004/G Seqirus Netherlands B.V., Rapporteur: Sol Ruiz Opinion adopted on 23.05.2019.	Positive Opinion adopted by consensus on 23.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Insuman - insulin human - EMA/H/C/000201/II/0128/G Sanofi-Aventis Deutschland GmbH, Rapporteur: Bart Van der Schueren	Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 16.05.2019.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0073**

Merck Sharp & Dohme B.V., Rapporteur: Daniela
Melchiorri

Request for Supplementary Information adopted
on 29.05.2019.

Request for supplementary information adopted
with a specific timetable.

**Macimorelin Aeterna Zentaris - macimorelin
- EMA/H/C/004660/II/0001**

Aeterna Zentaris GmbH, Rapporteur: Martina
Weise

Opinion adopted on 02.05.2019.

Positive Opinion adopted by consensus on
02.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

**Miglustat Gen.Orph - miglustat -
EMA/H/C/004366/II/0003**

Gen.Orph, Generic, Generic of Zavesca,
Rapporteur: Milena Stain

Request for Supplementary Information adopted
on 23.05.2019, 08.11.2018.

Request for supplementary information adopted
with a specific timetable.

**Movymia - teriparatide -
EMA/H/C/004368/II/0012**

STADA Arzneimittel AG, Duplicate, Duplicate of
Terrosa, Rapporteur: Milena Stain

Opinion adopted on 23.05.2019.

Positive Opinion adopted by consensus on
23.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

**Myalepta - metreleptin -
EMA/H/C/004218/II/0004, Orphan**

Aegerion Pharmaceuticals B.V., Rapporteur: Bart
Van der Schueren

Request for Supplementary Information adopted
on 02.05.2019.

Request for supplementary information adopted
with a specific timetable.

**Natpar - parathyroid hormone -
EMA/H/C/003861/II/0013/G, Orphan**

Shire Pharmaceuticals Ireland Limited,
Rapporteur: Bart Van der Schueren

Request for Supplementary Information adopted
on 29.05.2019, 31.01.2019.

Request for supplementary information adopted
with a specific timetable.

**Ogivri - trastuzumab -
EMA/H/C/004916/II/0003/G**

Mylan S.A.S, Rapporteur: Koenraad Norga

Request for Supplementary Information adopted
on 02.05.2019.

Request for supplementary information adopted
with a specific timetable.

**Onpattro - patisiran -
EMA/H/C/004699/II/0004/G, Orphan**

Alnylam Netherlands B.V., Rapporteur: Kristina
Dunder

Request for Supplementary Information adopted
on 29.05.2019.

Request for supplementary information adopted
with a specific timetable.

<p>Orphacol - cholic acid - EMA/H/C/001250/II/0025, Orphan Laboratoires CTRS, Rapporteur: Greg Markey Opinion adopted on 29.05.2019. Request for Supplementary Information adopted on 28.02.2019, 11.10.2018.</p>	<p>Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Prasugrel Mylan - prasugrel - EMA/H/C/004644/II/0003/G Mylan S.A.S, Generic, Generic of Efient, Rapporteur: Alar Irs Request for Supplementary Information adopted on 16.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Respreeza - human alpha1-proteinase inhibitor - EMA/H/C/002739/II/0029/G CSL Behring GmbH, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 02.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMA/H/C/000973/II/0132 GlaxoSmithkline Biologicals SA, Rapporteur: Kristina Dunder Opinion adopted on 29.05.2019. Request for Supplementary Information adopted on 28.03.2019.</p>	<p>Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Terrosa - teriparatide - EMA/H/C/003916/II/0010 Gedeon Richter Plc., Rapporteur: Milena Stain Opinion adopted on 23.05.2019.</p>	<p>Positive Opinion adopted by consensus on 23.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Trumenba - meningococcal group B vaccine (recombinant, adsorbed) - EMA/H/C/004051/II/0016/G Pfizer Europe MA EEIG, Rapporteur: Johann Lodewijk Hillege Opinion adopted on 16.05.2019. Request for Supplementary Information adopted on 14.03.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Tysabri - natalizumab - EMA/H/C/000603/II/0113/G Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.05.2019. Request for Supplementary Information adopted on 04.04.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Visudyne - verteporfin - EMA/H/C/000305/II/0098/G Novartis Europharm Limited, Rapporteur:</p>	<p>Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP</p>

<p>Alexandre Moreau Opinion adopted on 29.05.2019. Request for Supplementary Information adopted on 04.04.2019.</p>	<p>recommendation.</p>
<p>Zytiga - abiraterone acetate - EMEA/H/C/002321/II/0056/G Janssen-Cilag International NV, Rapporteur: Jorge Camarero Jiménez Request for Supplementary Information adopted on 29.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>WS1464/G Revatio-EMEA/H/C/000638/WS1464/0084/G Viagra-EMEA/H/C/000202/WS1464/0100/G Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 23.05.2019. Request for Supplementary Information adopted on 21.03.2019.</p>	<p>Positive Opinion adopted by consensus on 23.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1500/G HyQvia-EMEA/H/C/002491/WS1500/0045/G Kiovig-EMEA/H/C/000628/WS1500/0086/G Baxter AG, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.05.2019. Request for Supplementary Information adopted on 17.01.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1502 Fertavid-EMEA/H/C/001042/WS1502/0042 Puregon-EMEA/H/C/000086/WS1502/0100 Merck Sharp & Dohme B.V., Lead Rapporteur: Nithyanandan Nagercoil Opinion adopted on 16.05.2019. Request for Supplementary Information adopted on 07.03.2019, 06.12.2018.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1567 Ambirix-EMEA/H/C/000426/WS1567/0097 Twinrix Adult-EMEA/H/C/000112/WS1567/0132 Twinrix Paediatric-EMEA/H/C/000129/WS1567/0133 GlaxoSmithkline Biologicals SA, Lead</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

Rapporteur: Bart Van der Schueren
Opinion adopted on 16.05.2019.

WS1600/G

**Aflunov-EMEA/H/C/002094/WS1600/
0049/G**

**Foclivia-EMEA/H/C/001208/WS1600/
0044/G**

Seqirus S.r.l, Lead Rapporteur: Daniela
Melchiorri

Request for Supplementary Information adopted
on 23.05.2019.

Request for supplementary information adopted
with a specific timetable.

**Hexacima-EMEA/H/C/002702/WS1575/
0088/G**

**Hexaxim-EMEA/H/W/002495/WS1575/
0093/G**

**Hexyon-EMEA/H/C/002796/WS1575/
0092/G**

Sanofi Pasteur, Lead Rapporteur: Jan
Mueller-Berghaus

Opinion adopted on 29.05.2019.

Positive Opinion adopted by consensus on
29.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Adenuric - febuxostat -

EMEA/H/C/000777/II/0051

Menarini International Operations Luxembourg
S.A., Rapporteur: Andrea Laslop, "Update of
section 5.1 of the SmPC in order to include the
results of the clinical safety study CARES
(TMX-67_301), to compare the cardiovascular
outcomes of febuxostat and allopurinol in
subjects with gout and cardiovascular
comorbidities; this is a Multicenter, Randomized,
Active-Control, Phase 3B Study.

In addition, the Marketing authorisation holder
(MAH) took the opportunity to provide a
consolidated Module 2.7.6 in order to list all the
synopsis of individual studies in a unique tabular
format."

Request for Supplementary Information adopted
on 29.05.2019, 28.03.2019, 13.12.2018,
04.10.2018.

Request for supplementary information adopted
with a specific timetable.

Bosulif - bosutinib -

EMEA/H/C/002373/II/0037

Pfizer Europe MA EEIG, Rapporteur: Janet
Koenig, PRAC Rapporteur: Martin Huber, "Update
of sections 4.6 and 5.3 of the SmPC based on final
results from An Oral (Gavage) Study of the
Effects of PF-05208763 on Pre- and Postnatal

Positive Opinion adopted by consensus on
16.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

Development, Including Maternal Function in Rats listed as a category 3 study in the RMP. The Package leaflet is updated accordingly. The updated RMP version 4.5 has also been submitted."

Opinion adopted on 16.05.2019.

**Brilique - ticagrelor -
EMA/H/C/001241/II/0044**

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4 of the SmPC in order to add a warning on Thrombotic Thrombocytopenic Purpura (TTP) and update of section 4.8 of the SmPC to include TTP as new adverse drug reaction with a frequency 'unknown', based on a safety review. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make some formatting corrections throughout the product information."

Opinion adopted on 29.05.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Brilique - ticagrelor -
EMA/H/C/001241/II/0045**

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.4 of the SmPC in order to add a new warning on interference with laboratories tests regarding platelet function tests to diagnose heparin induced thrombocytopenia (HIT) based on as safety review."

Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**Brinavess - vernakalant -
EMA/H/C/001215/II/0034**

Correvio, Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.8 and 5.1 of the SmPC based on the final results from the non-interventional PASS SPECTRUM study, listed as a category 3 study in the RMP, in order to fulfil MEA 026.5; SPRECTRUM (6621-019) study is a prospective observational registry study to characterise normal conditions of use, dosing and safety following administration of vernakalant IV sterile concentrate."

Request for Supplementary Information adopted on 16.05.2019, 14.02.2019.

Request for supplementary information adopted with a specific timetable.

**Cetrotide - cetrorelix -
EMA/H/C/000233/II/0068**

Merck Europe B.V., Rapporteur: Martina Weise,

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

<p>“Update of section 4.2 of the SmPC based on literature review to add an alternative option for the treatment initiation to start once the leading follicle(s) reach a size that could lead to premature LH (Luteinizing Hormone) surge and ovulation.</p> <p>The Package Leaflet (PL) is updated in accordance. Correction in section 3 of the PL regarding the timing of ovulation induction. In addition, the Marketing authorisation holder (MAH) took the opportunity to delete the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest QRD template version 10.0.”</p> <p>Opinion adopted on 29.05.2019.</p> <p>Request for Supplementary Information adopted on 28.02.2019, 18.10.2018.</p>	<p>recommendation.</p>
<p>Cinryze - C1 esterase inhibitor (human) - EMEA/H/C/001207/II/0069</p> <p>Shire Services BVBA, Rapporteur: Jan Mueller-Berghaus, “Update of section 4.8 of the SmPC following a company review of the safety data base. The PL is updated accordingly.”</p> <p>Request for Supplementary Information adopted on 16.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Defitelio - defibrotide - EMEA/H/C/002393/II/0039, Orphan</p> <p>Gentium S.r.l., Rapporteur: Kristina Dunder, “Update of section 5.1 of the SmPC to amend the mechanism of action with new data on non-clinical studies identified from published literature.”</p> <p>Opinion adopted on 02.05.2019.</p> <p>Request for Supplementary Information adopted on 14.03.2019.</p>	<p>Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>Eliquis - apixaban - EMEA/H/C/002148/II/0059</p> <p>Bristol-Myers Squibb / Pfizer EEIG, Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2, 4.3, 4.4 and 4.5 of the SmPC based on the current European Society of Cardiology (ESC) guideline for direct oral anti-coagulants (DOACs) and the literature including the AXAFA-AFNET 5 study, a major investigator’s sponsored trial with apixaban, in order to include an exception to the contraindicated concomitant treatment with any other anticoagulant agent for heparin co-administration during catheter ablation for atrial fibrillation. The Package Leaflet is updated</p>	<p>Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to clarify the wording in section 4.2 of the SmPC to include a reference to transesophageal echocardiogram (TEE) guided cardioversion.”
Opinion adopted on 29.05.2019.
Request for Supplementary Information adopted on 28.02.2019.

**EXJADE - deferasirox -
EMA/H/C/000670/II/0066**

Novartis Europharm Limited, Rapporteur:
Alexandre Moreau, “To update the Exjade SmPC (Section 5.1) to reflect the results of clinical study C1CL670A2302 (TELESTO) with Exjade in patients with myelodysplastic syndrome (MDS).”
Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**Eylea - aflibercept -
EMA/H/C/002392/II/0052**

Bayer AG, Rapporteur: Alexandre Moreau,
“Update of section 5.1 of the SmPC in order to reflect the final results from ALTAIR (SN17668) study; this is a randomized, open-label phase 4 study evaluating the efficacy and safety of repeated doses of intravitreal aflibercept with variable treatment intervals in Japanese subjects with neovascular age-related macular degeneration. In addition, the Marketing authorisation holder (MAH) took the opportunity to include minor editorial changes in section 5.1 of the SmPC.”
Opinion adopted on 29.05.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Fasenra - benralizumab -
EMA/H/C/004433/II/0013**

AstraZeneca AB, Rapporteur: Fátima Ventura,
“Update of sections 4.8 and 5.1 of the SmPC in order to reflect the final results from study D3250C00021 (BORA) listed as a category 3 in the RMP; this is a randomised phase 3 study to evaluate the safety and tolerability of benralizumab in asthmatic adults and adolescents on inhaled corticosteroid plus long-acting β 2 agonist agents. In addition, section 4.2 of the SmPC is updated to reflect the age group defined in the PIP waiver.”
Opinion adopted on 29.05.2019.
Request for Supplementary Information adopted on 11.04.2019, 14.02.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Firdapse - amifampridine -

Positive Opinion adopted by consensus on

EMA/H/C/001032/II/0060, Orphan
BioMarin International Limited, Rapporteur:
Kristina Dunder, "Update section 5.1 of the SmPC to include results from study LMS-003: a double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of amifampridine in patients with Lambert-Eaton Myasthenic Syndrome (LEMS)."
Opinion adopted on 16.05.2019.
Request for Supplementary Information adopted on 17.01.2019.

16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Gilenya - fingolimod -
EMA/H/C/002202/II/0053
Novartis Europharm Limited, Rapporteur:
Alexandre Moreau, "Type II (C.I.4):
- to update section 4.4 of the SmPC (subsection 'Return of disease activity (rebound)' and subsection 'Stopping therapy') to add information to prescriber's on the timing of reported events and further recommendations on monitoring of patients.
- to update section 4.6 of the SmPC to add a warning for women stopping treatment for the purpose of becoming pregnant and for pregnant women, and addition of a cross-reference to section 4.4 subsection 'Return of disease activity (rebound)'.
- to update section 4.8 of the SmPC to add a new adverse reaction 'Severe exacerbation of disease after Gilenya discontinuation' with frequency 'Not known'.
The package leaflet is updated accordingly."
Request for Supplementary Information adopted on 29.05.2019, 07.03.2019.

Request for supplementary information adopted with a specific timetable.

Humira - adalimumab -
EMA/H/C/000481/II/0187
AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC to reflect results from the final report from study M11-327: A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis; listed as a category 3 study in the RMP. Furthermore editorial changes and a brief description of the study design were also added to section 5.1 of the SmPC."
Opinion adopted on 16.05.2019.
Request for Supplementary Information adopted

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

on 14.03.2019.

IBRANCE - palbociclib -

EMA/H/C/003853/II/0016

Pfizer Europe MA EEIG, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update with information following submission of the final results from study the pivotal Study A5481023 "A double blind, Phase 3 trial of fulvestrant with or without palbociclib in pre- and postmenopausal women with hormone receptor positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy" listed as a recommendation at the time of initial MA."

Request for Supplementary Information adopted on 02.05.2019, 31.01.2019.

Request for supplementary information adopted with a specific timetable.

Imbruvica - ibrutinib -

EMA/H/C/003791/II/0048, Orphan

Janssen-Cilag International NV, Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC Special warnings and precautions for use in order to add a warning under "bleeding-related events" based on the final clinical study reports results to evaluate the risks of major hemorrhage with the administration of Imbruvica (ibrutinib)). The study is listed in section III.2 additional Pharmacovigilance Activities A non-interventional PASS clinical study report (CSR) for serious haemorrhage in the RMP.

In addition, the Marketing authorisation holder (MAH) took the opportunity to include a minor edit in the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 29.05.2019, 14.03.2019.

Request for supplementary information adopted with a specific timetable.

Increlex - mecasermin -

EMA/H/C/000704/II/0059

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, "Submission of the final analysis for the Category 3, Additional Pharmacovigilance Activity MEA 020.3, on Lowest Effective Dose for mecasermin. No changes to the SmPC or Patient Leaflet are proposed as part of this final analysis on Lowest Effective Dose of mecasermin."

Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

Kanuma - sebelipase alfa -

EMA/H/C/004004/II/0019, Orphan

Alexion Europe SAS, Rapporteur: Bart Van der

Request for supplementary information adopted with a specific timetable.

Schueren, "Submission of the final report from study LAL-CL04, in order to fulfil this recommendation (REC). This is an open label multicentre extension study to evaluate the long-term safety, tolerability and efficacy of sebelipase alfa in adult subjects with liver dysfunction due to lysosomal acid lipase deficiency who previously received treatment in study LAL-CL01."

Request for Supplementary Information adopted on 29.05.2019, 21.03.2019.

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0071**

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, "To update sections 4.2, 4.8, 5.1 and 5.2 of the SmPC based on interim results from study KEYNOTE-051; this is a ongoing Phase I/II, single-arm study to evaluate the PK, pharmacodynamics, toxicity, safety, and anti-tumour activity of pembrolizumab in paediatric participants (Measure 2 of PIP01). Additionally, the results of study PD018 / PA-0064; evaluation of expression of PD-1, PD-L1, and PD-L2 in archival paediatric tumour tissues, were submitted (Measure 1 of PIP01)."

Request for Supplementary Information adopted on 02.05.2019.

Request for supplementary information adopted with a specific timetable.

**Kolbam - cholic acid -
EMA/H/C/002081/II/0028, Orphan**

Retrophin Europe Ltd, Rapporteur: Constantinos Markopoulos, "Submission of the final report from study CAC-002-01, listed as a category 3 study in the RMP. This is a Phase 3, open-label, single arm, non-randomized study investigating cholic acid in the treatment of subjects with inborn errors of bile acid metabolism. The study was a continuation study that included eligible subjects who had previously received cholic acid in studies CAC-91-10-10 or CAC-001-01 as well as newly diagnosed subjects."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

Request for supplementary information adopted with a specific timetable.

**Lynparza - olaparib -
EMA/H/C/003726/II/0028**

AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of section 5.2 of the SmPC in order to include information on the in vitro effect of olaparib on UGT enzymes based on results from

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

in vitro assays. In addition, the MAH is proposing to change the due date for submission of the final CSR of the phase IV, open label, single arm study (D0816C00012/ORZORA) in patients with relapsed platinum sensitive ovarian cancer who are in response following platinum-based chemotherapy and who carry loss of function germline or somatic BRCA mutations, listed as a PAES in the Annex II."

Opinion adopted on 16.05.2019.

**Mekinist - trametinib -
EMA/H/C/002643/II/0033**

Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.4 and 4.8 of the SmPC to introduce a warning and new ADRs related to severe cutaneous adverse reactions (SCARs) as per request in the outcome of EMA/H/C/PSUSA/00010084/201808 for dabrafenib. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to include some editorial changes in sections 4.4, 4.6 and 4.8 of the SmPC."

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 14.03.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Menveo - meningococcal group a, c, w135
and y conjugate vaccine -
EMA/H/C/001095/II/0083**

GSK Vaccines S.r.l, Rapporteur: Johann Lodewijk Hillege, "Update of section 4.5 of the SmPC in order to include reference to concomitant administration with Meningococcal group B vaccine, based on results from study V72_56, previously submitted and assessed as part of procedure P46/035 for Menveo. The Package Leaflet (Section 2) is updated accordingly."

Opinion adopted on 29.05.2019.

Request for Supplementary Information adopted on 28.03.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Natpar - parathyroid hormone -
EMA/H/C/003861/II/0018/G, Orphan**

Shire Pharmaceuticals Ireland Limited, Rapporteur: Bart Van der Schueren, "Update of sections 4.4 and 4.8 of the SmPC in order to include information related to the potential risk of hypersensitivity reactions based on the review of cumulative postmarketing safety data, as well as

Request for supplementary information adopted with a specific timetable.

the postmarketing cases of hypersensitivity with a frequency of unknown.

Update of section 4.4 of the SmPC in order to include information related to the potential risk of seizure due to severe hypocalcemia, to add a warning based on the review of cumulative postmarketing safety data.

The Package Leaflet has been revised accordingly."

Request for Supplementary Information adopted on 23.05.2019.

Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0146

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to add decreased neutrophil count to the list of adverse reactions with the frequency unknown. The Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to sections 4.2, 4.4, 4.8 and 5.1 of the SmPC and to the Package Leaflet."

Opinion adopted on 02.05.2019.

Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0147

CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, "Update of section 2 of the SmPC in order to update the IgG subclass values according to performed analyses. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives for Bulgaria in the Package Leaflet."

Opinion adopted on 16.05.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Repatha - evolocumab - EMEA/H/C/003766/II/0033

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 4.8 of the SmPC in order to update the safety information with regards to the adverse reaction "Influenza-like illness" with a frequency of Uncommon following the assessment of influenza-like illness with evolocumab in both the clinical database and postmarketing database. The Package Leaflet section 4 was updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement changes to the package leaflet

Request for supplementary information adopted with a specific timetable.

section 2 subsequent to the revised Annex to the EC guideline on excipients in the labelling (EMA/CHMP/302620/2017) to update the wording for sodium.”

Request for Supplementary Information adopted on 29.05.2019.

Spinraza - nusinersen - EMEA/H/C/004312/II/0013/G, Orphan

Biogen Netherlands B.V., Rapporteur: Bruno Sepodes, “C1.3.b (Type II): to update sections 4.8 and 5.1 of the SmPC following assessment of the final CSR for Study CS3A (Procedure number: EMA/H/C/4312/P46/007). Study CS3A was a phase 2 open-label multiple dose study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Nusinersen (ISIS 396443) Delivered Intrathecally to Patients with Infantile-Onset Spinal Muscular Atrophy. 3x.C.I.4 (Type II): to update sections 4.8 and 5.1 of the SmPC to reflect safety, efficacy, and immunogenicity data from the interim analyses of studies SM201 and CS11, and results of SM202, Part 1.

SM202 (EMBRACE) is a 2-part Phase 2 study in subjects with infantile- and later-onset SMA not eligible to participate in Studies CS3B or CS4.

CS11 (SHINE) is an on-going open label extension Phase 3 study for subjects with infantile and later onset SMA who previously participated in investigational studies of nusinersen, including Studies CS3A, CS12, CS3B, and CS4 and SM202.

SM201 (NURTURE) is an on-going multicentre, Phase 2, open label study in infants with genetically diagnosed, presymptomatic SMA.”

Opinion adopted on 02.05.2019.

Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391/II/0017/G

Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information based on week-96 results from studies TMC114FD2HTX3001 (AMBER) “A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of D/C/F/TAF once daily fixed-dose combination regimen versus a regimen consisting of DRV/COBI FDC co-administered with FTC/TDF

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

FDC in ARV treatment-naïve HIV-1 infected subjects”, and study TMC114IFD3013 (EMERALD) “A Phase 3, randomized, active-controlled, open-label study to evaluate switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor combined with FTC/TDF in virologically-suppressed, HIV-1 infected subjects”, both listed as category 3 studies in the RMP. The Package Leaflet is updated accordingly. The RMP version 5.2 (in version 2 of the RMP template) has also been submitted to reflect the study results and revise due dates for category 3 studies GS-US-311-1717 and GS-US-292-0109. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.2 of the SmPC and Package Leaflet to include advice in the event of vomiting in line with the approved Genvoya SmPC and make minor editorial changes in the SmPC; as well as to update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.0.”

Opinion adopted on 29.05.2019.

Tafinlar - dabrafenib -

EMA/H/C/002604/II/0038

Novartis Europharm Limited, Rapporteur: Filip Josephson, “Update of section 4.6 of the SmPC in order to update information on fertility, pregnancy and lactation after routine review of the company core data sheet, taking into consideration the original source documentation from GSK (former MAH), current scientific knowledge, published literature, as well as health authority and working group guidelines. The package leaflet is being updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to include some editorial changes in sections 4.4 and 4.8 of the SmPC and in section 4 of the package leaflet.”

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 14.03.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Tecentriq - atezolizumab -

EMA/H/C/004143/II/0023

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC in order to include new ADRs identified in IMmotion150 and IMmotion151 studies. The

Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

revision of the list of ADRs is supported by a drug safety report reflecting the ADRs in the updated pool of patients for monotherapy (n=3178) and combination therapy (n=1345).

The Package Leaflet is updated accordingly."

Opinion adopted on 02.05.2019.

**Tremfya - guselkumab -
EMA/H/C/004271/II/0010**

Janssen-Cilag International N.V., Rapporteur:
Agnes Gyurasics, "Update of sections 4.8 and 5.1 of the SmPC to add the long term 3-year clinical data from the two ongoing clinical studies CANTO1959PSO3001 (VOYAGE 1) and CANTO1959PSO3002 (VOYAGE 2) in subjects with plaque psoriasis."

Request for Supplementary Information adopted on 02.05.2019, 14.03.2019.

Request for supplementary information adopted with a specific timetable.

**Veltassa - patiomer -
EMA/H/C/004180/II/0007**

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2, 4.5 and 5.1 of the SmPC to reflect the results of study RLY5016-401, an Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiomer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE). The PL has been updated accordingly."

Opinion adopted on 02.05.2019.

Request for Supplementary Information adopted on 14.03.2019, 17.01.2019.

Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Verzenio - abemaciclib -
EMA/H/C/004302/II/0003**

Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, "Update of section 4.2 of the SmPC in order to add a criterion for discontinuing abemaciclib in the event of specific hepatic changes based on available safety data. In addition, the Marketing authorisation holder (MAH) took the opportunity to make editorial changes to section 5.1 of the SmPC."

Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**XALKORI - crizotinib -
EMA/H/C/002489/II/0062**

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, "Submission of the review of the PK profile of the crizotinib lactam metabolite, PF-06260182 in subjects or patients treated with

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

single agent crizotinib, and discussion of the clinical relevance of these findings derived from the following reports: A8081001, A8081002, A8081005, A8081006, A8081007, A8081012, A8081014 and A8081020, in order to fulfill a CHMP recommendation. Based on the data discussed as part of this variation, no update of the Product Information is warranted.”
Opinion adopted on 29.05.2019.

**Xarelto - rivaroxaban -
EMA/H/C/000944/II/0064**

Bayer AG, Rapporteur: Kristina Dunder, “Submission of the final report from an interventional phase III study (COMMANDER HF, 2.5 mg rivaroxaban compared to placebo).”
Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

**Zinforo - ceftaroline fosamil -
EMA/H/C/002252/II/0038**

Pfizer Ireland Pharmaceuticals, Rapporteur: Greg Markey, “Update of section 4.2 of the SmPC to amend the recommended duration of ceftaroline fosamil intravenous (IV) infusion for standard dose regimens in adults and children. The PL is updated accordingly. In addition the MAH has also taken the opportunity to reformat section 4.2 of the SmPC Posology and method of administration and to incorporate minor editorial updates to sections 4.4, 4.8, 5.1, 5.2 and 5.3 of the SmPC.”
Opinion adopted on 29.05.2019.
Request for Supplementary Information adopted on 28.03.2019, 20.09.2018.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**WS1566
Biktarvy-EMA/H/C/004449/WS1566/
0017
Descovy-EMA/H/C/004094/WS1566/
0041
Genvoya-EMA/H/C/004042/WS1566/
0061
Odefsey-EMA/H/C/004156/WS1566/
0041
Vemlidy-EMA/H/C/004169/WS1566/
0019**

Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, “Update of section 4.8 of the SmPC following a safety review by the MAH assessing the clinical evidence of a causal association between tenofovir

Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

alafenamide-containing products and two adverse events, angioedema and urticaria. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor linguistic amendments and editorial changes to the Odefsey and Vemlidy products information."

Opinion adopted on 02.05.2019.

WS1588

Aluvia-EMEA/H/W/000764/WS1588/0109
Kaletra-EMEA/H/C/000368/WS1588/0177
Norvir-EMEA/H/C/000127/WS1588/0154

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.3 and 4.5 of the SmPC in order to include information on the contraindication with neratinib and interactions with abemaciclib, neratinib and glecaprevir/pibrentasvir. In addition, the Worksharing applicant (WSA) took the opportunity to update section 4.5 of the SmPC of Kaletra and Aluvia to add information on the interaction of lopinavir/ritonavir with sofosbuvir/velpatasvir/voxilaprevir, as well as to remove information on the interaction with boceprevir and telaprevir since these medicinal products have been withdrawn from the EU market. Furthermore, the quantity of tenofovir disoproxil has been amended as 300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil in sections 4.5 and 5.1 of the Kaletra and Aluvia SmPCs (as requested during procedure WS 1555). The Package Leaflets are updated accordingly."

Opinion adopted on 29.05.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

WS1605

Lyrica-EMEA/H/C/000546/WS1605/0097
Pregabalin Pfizer-EMEA/H/C/003880/
WS1605/0027

Pfizer Europe MA EEIG, Lead Rapporteur: Johann Lodewijk Hillege, "Addition in the SmPC section 4.5 of the wording on the risk of death, including in patients who are substance abusers."

Request for Supplementary Information adopted on 23.05.2019.

Request for supplementary information adopted with a specific timetable.

WS1607

Kispilix-EMEA/H/C/004224/WS1607/0023
Lenvima-EMEA/H/C/003727/WS1607/
0025

Eisai GmbH, Lead Rapporteur: Bart Van der

Request for supplementary information adopted with a specific timetable.

Schueren, "Update of section 5.2 of the SmPC in order to include information about the results of Study E7080-A001- 010, "A Multicenter Phase 0 Study in Healthy Subjects and Subjects with Either Hepatic or Renal Impairment to Obtain Plasma for Assessment in Vitro Lenvatinib Protein Binding"."

Request for Supplementary Information adopted on 23.05.2019.

B.5.3. CHMP-PRAC assessed procedures

Aflunov - prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) -

EMA/H/C/002094/II/0044/G

Seqirus S.r.l, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Amelia Cupelli, "Update of sections 4.4, 4.6, 4.8 and 5.1 of the SmPC following clinical study reports of studies V87_25 and V87_26 listed as post approval commitments; these are Phase 3, stratified, randomized, controlled, observer-blind, multicenter studies; the Package Leaflet and Labelling are updated accordingly.

The updated RMP version 3.0 has also been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to implement some amendments to the PI and make some additional minor editorial corrections."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019, 20.09.2018.

Request for supplementary information adopted with a specific timetable.

Avonex - interferon beta-1a -

EMA/H/C/000102/II/0182/G

Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon, "2x type II (C.I.4):

1) Update of sections 4.3 and 4.6 of the SmPC in order to add information about pregnancy information and update the statement regarding breast-feeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register-based study in the Nordic countries (EUPAS13054).

2) Update of section 4.6 of the SmPC in order to update the statement regarding breast-feeding following a review of studies, case reports and literature articles.

Request for supplementary information adopted with a specific timetable.

The Package leaflet has been updated accordingly.

This submission fulfils MEA 87.2 and 84."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

**Benlysta - belimumab -
EMA/H/C/002015/II/0065**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on suicidality and depression based on interim results from study BEL115467 listed in the Annex II; this is a Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab; the Package Leaflet is updated accordingly. The RMP version 30 has also been endorsed. In addition, a Direct Healthcare Professional Communication (DHPC) and a communication plan were endorsed to increase awareness and provide guidance to Healthcare Professionals."

Opinion adopted on 29.05.2019.

Request for Supplementary Information adopted on 28.03.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Betaferon - interferon beta-1b -
EMA/H/C/000081/II/0124/G**

Bayer AG, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "2x type II (C.I.4):
1) Update of sections 4.3 and 4.6 of the SmPC in order to add information about pregnancy information and update the statement regarding breast-feeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register-based study in the Nordic countries (EUPAS13054).

2) Update of section 4.6 of the SmPC in order to update the statement regarding breast-feeding following a review of studies, case reports and literature articles.

The Package leaflet has been updated accordingly.

This submission fulfils MEA 024.2 and 21.

An updated RMP version 4.1 is included in the submission, including the deletion of the important potential risk 'Pregnancy outcomes' and an update of the EU-RMP template (rev.2)."

Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

**Champix - varenicline -
EMA/H/C/000699/II/0074**

Pfizer Europe MA EEIG, Rapporteur: Mark Ainsworth, PRAC Rapporteur: Anette Kirstine Stark, "Update of sections 4.2, 5.1 and 5.2 of the SmPC to reflect results of the paediatric study A3051073 (MEA 047) " A Phase 4, Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study With Follow-Up, Evaluating The Safety And Efficacy Of Varenicline For Smoking Cessation In Healthy Adolescent Smokers." The PL is updated accordingly. RMP version 11.1 was submitted." Opinion adopted on 16.05.2019.
Request for Supplementary Information adopted on 14.03.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Darzalex - daratumumab -
EMA/H/C/004077/II/0027, Orphan**

Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.4 and 4.8 of the SmPC to introduce a new warning and to add the recently identified risk of Hepatitis B reactivation as an uncommon adverse drug reaction, respectively. The PL and the RMP (v. 5.0 rev2) are amended accordingly. A DHPC to inform prescribers on the newly identified risk has been agreed." Opinion adopted on 29.05.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Extavia - interferon beta-1b -
EMA/H/C/000933/II/0096/G**

Novartis Europharm Limited, Informed Consent of Betaferon, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, "2x type II (C.I.4):
1) Update of sections 4.3 and 4.6 of the SmPC in order to add information about pregnancy information and update the statement regarding breast-feeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register-based study in the Nordic countries (EUPAS13054).
2) Update of section 4.6 of the SmPC in order to update the statement regarding breast-feeding following a review of studies, case reports and literature articles.
The Package leaflet has been updated

Request for supplementary information adopted with a specific timetable.

accordingly.

This submission fulfils MEA 022.2 and 019.

An updated RMP version 4.1 is included in the submission, including the deletion of the important potential risk 'Pregnancy outcomes' and an update of the EU-RMP template (rev. 2)."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

**Fasenra - benralizumab -
EMA/H/C/004433/II/0014/G**

AstraZeneca AB, Rapporteur: Fátima Ventura,
PRAC Rapporteur: David Olsen, "B.IV.1.c – To add an autoinjector delivery device, Fasenra 30 mg solution for injection in pre-filled pen.

C.I.4 – Update of sections 4.2, 6.4, 6.5 and 6.6 of the SmPC in order to update the information for self-administration for Fasenra 30 mg solution for injection in pre-filled syringe. The labelling and the package leaflet are updated accordingly.

In addition, the RMP (version 2.0) is updated to reflect the information about the new presentation, to include additional information about completed studies (ALIZE, GREGALE, AMES, GRECO), to add updated exposure data post MAA approval, and to reflect additional details on the post-authorisation safety studies (Pregnancy registry (D3250R00026) and Malignancy Post Authorization Safety Study (D3250R00042)). Furthermore, the RMP is revised in line with the RMP template (GVP Module V rev.2)."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

Request for supplementary information adopted with a specific timetable.

**Ferriprox - deferiprone -
EMA/H/C/000236/II/0128**

Apotex B.V., Rapporteur: Alexandre Moreau,
PRAC Rapporteur: Ghania Chamouni, "Update section 4.4 of the SmPC and the patient/carer reminder card in order to update and change the recommended frequency of ANC monitoring throughout Ferriprox treatment from a weekly basis to every week for the first six months of Ferriprox therapy, once every two weeks after six months of Ferriprox therapy, and to monthly after one year of therapy. The package leaflet has been updated accordingly. The RMP version 13.2 has also been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update minor linguistic amendments in the HU and MT product

Request for supplementary information adopted with a specific timetable.

information.”

Request for Supplementary Information adopted on 16.05.2019, 29.11.2018.

Gazyvaro - obinutuzumab - EMEA/H/C/002799/II/0034, Orphan

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Ulla Wändel Liminga, “Submission of the final results of the pivotal study BO21005/GOYA to address the additional pharmacovigilance activities required in the EU RMP. Consequently the updated RMP version 5.0 has been submitted.”

Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

Jakavi - ruxolitinib - EMEA/H/C/002464/II/0040

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Update of section 5.3 of the SmPC based on final results from studies from the juvenile toxicity studies 1570143 (dose range finding juvenile study) and 157014 (juvenile development study). An updated RMP version 10 was submitted accordingly. The RMP was also updated in line with the template of the GVP Module V Rev.2 (EMA/838713/2011 Rev 2). Finally, the RMP changes requested by the PRAC in the latest PSUR (PSUSA-10015-201802) have been also implemented in this RMP.

In addition, the MAH has taken the opportunity to align this RMP to the revised RMP template and to the GVP Module V Rev.2 (EMA/838713/2011 Rev 2).”

Opinion adopted on 16.05.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Jakavi - ruxolitinib - EMEA/H/C/002464/II/0041

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Update of section 4.5 of the SmPC based on the final results of a Drug-Drug Interaction (DDI) study INC4242A2106, fulfilling a Post-Authorisation Measure (MEA 0016) requested as part of a previous type II variation (Procedure No. EMEA/H/C/002464/II/0025). The study INC4242A2106 evaluated the effect of multiple doses of fluconazole on the pharmacokinetics of ruxolitinib administered as a single dose in an open-label, crossover study in healthy subjects. An updated RMP version 10 was

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

submitted accordingly. Furthermore, the RMP template was adapted to revision 2 in line with GVP Module V Rev.2 (EMA/838713/2011 Rev 2).”
Opinion adopted on 16.05.2019.

Mimpara - cinacalcet -

EMA/H/C/000570/11/0062/G

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, “Update of section 4.2 of the SmPC to provide additional information with reference to switching from etelcalcetide to Mimpara (cinacalcet), upon request by PRAC following the assessment of the etelcalcetide PSUR (dated 14 June 2018). Further, the term ‘silica, dental type’ has been replaced by ‘Amorphous silicon dioxide’ in SmPC section 6.1.

An updated RMP version 9.0 was provided as part of the application in order to align the RMP with the GVP Module V (template Rev 2) with consequential reclassification of existing safety concerns.”

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 14.03.2019, 29.11.2018.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Mysimba - naltrexone hydrochloride / bupropion hydrochloride -

EMA/H/C/003687/11/0029/G

Orexigen Therapeutics Ireland Limited, Rapporteur: Mark Ainsworth, PRAC Rapporteur: Martin Huber, “Group of variations consisting of the:

2) C.I.3.b: to update section 4.8 on the list of adverse drug reactions and their corresponding frequencies following the PRAC outcome on PSUR procedure (PSUSA/10366/201709).

2) C.I.4: to update sections 4.2,4.4 and 5.2 of the SmPC to add results from a phase I open label parallel study to evaluate the pharmacokinetics of a single oral dose of extended-release combination of naltrexone and bupropion in subjects with normal hepatic function or varying degrees of impaired hepatic function and remove the recommendation to not use naltrexone/bupropion in patients with mild hepatic impairment. The existing warning has also been updated accordingly.

The warning related to contraindications has also been aligned to section 4.3 to add end-stage renal failure patients. Consequentially an updated RMP (version 11) has also been

Request for supplementary information adopted with a specific timetable.

submitted.

In addition, the MAH takes the opportunity to update the warning on lactose to be in accordance with EC guideline on Guideline on "Excipients in the labelling and package leaflet of medicinal products for human use".

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019, 15.11.2018.

**Nucala - mepolizumab -
EMA/H/C/003860/II/0021**

GlaxoSmithKline Trading Services Limited,
Rapporteur: Peter Kiely, PRAC Rapporteur:
Brigitte Keller-Stanislawski, "Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information based on final results from Study 200363 Part B and two open label extension studies (201312 and MEA115666) listed as category 3 studies in the RMP. These are interventional post-authorisation safety studies conducted to assess the long-term (52 weeks) safety and tolerability of mepolizumab when administered subcutaneously to patients aged 6 to 11 years old with severe eosinophilic asthma (study 200363 Part B), to describe the long-term safety profile of mepolizumab (MEA115666), and to provide extended treatment to subjects from study MEA115661 and further describe long-term safety in these subjects (study 201312). The RMP (version 5.0) has also been submitted to reflect the completion of the studies and to be aligned with GVP Module V, rev.2 template. The requested variation proposed amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP)."
Opinion adopted on 16.05.2019.
Request for Supplementary Information adopted on 14.03.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Pelgraz - pegfilgrastim -
EMA/H/C/003961/II/0005**

Accord Healthcare S.L.U., Rapporteur: Sol Ruiz,
PRAC Rapporteur: Menno van der Elst
Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**Plegridy - peginterferon beta-1a -
EMA/H/C/002827/II/0052/G**

Biogen Netherlands B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ulla Wändel Liminga, "2x type II (C.I.4):
1) Update of sections 4.3 and 4.6 of the SmPC in

Request for supplementary information adopted with a specific timetable.

order to add information about pregnancy information and update the statement regarding breast-feeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register-based study in the Nordic countries (EUPAS13054).

2) Update of section 4.6 of the SmPC in order to update the statement regarding breast-feeding following a review of studies, case reports and literature articles.

The Package leaflet has been updated accordingly.

This submission fulfils MEA 8.2 and 002.

An updated RMP version 4.1 is included in the submission, including the deletion of the important potential risk 'Pregnancy outcomes' and an update of the EU-RMP template (rev. 2)."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

**PREVYMIS - Ietermovir -
EMA/H/C/004536/II/0011, Orphan**

Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Kirsti Villikka, "Update of sections 4.4 and 4.5 of the SmPC in order to update the safety information following the final results of a clinical pharmacology trial entitled "A Study to Assess the Effect of Rifampin on the Single-Dose and Steady-State Pharmacokinetics of MK-8228 in Healthy Adult Subjects" (MK-8228-038) listed as a category 3 study in the RMP; the Package Leaflet is updated accordingly. The RMP version 2.1 has also been submitted."

Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**Rebif - interferon beta-1a -
EMA/H/C/000136/II/0137/G**

Merck Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga, "2x type II (C.I.4):

1) Update of sections 4.3, 4.6 and 5.3 of the SmPC in order to add information about pregnancy information and update the statement regarding breast-feeding following the completion of the European IFN Beta Pregnancy Registry (8th Annual and final report) and the Final CSR of the register-based study in the Nordic countries (EUPAS13054).

2) Update of section 4.6 of the SmPC in order to

Request for supplementary information adopted with a specific timetable.

update the statement regarding breast-feeding following a review of studies, case reports and literature articles.

The Package leaflet has been updated accordingly.

This submission fulfils MEA 43.2 and 39.

An updated RMP version 10.0 is included in the submission, including the deletion of the important potential risk 'Pregnancy outcomes' and an update of the EU-RMP template (rev.2)."

Request for Supplementary Information adopted on 29.05.2019, 28.02.2019.

**ReFacto AF - moroctocog alfa -
EMA/H/C/000232/II/0151**

Pfizer Europe MA EEIG, Rapporteur: Mark Ainsworth, PRAC Rapporteur: Anette Kirstine Stark, "To update sections 4.8 Undesirable effects and 5.1 Pharmacodynamic effects of the SmPC based on the final results from study 3082B2-313 (B1831001 - "An Open-Label Study to Evaluate Prophylaxis Treatment, and to Characterize the Efficacy, Safety, and Pharmacokinetics of B-Domain Deleted Recombinant Factor VIII Albumin Free (Moroctocog Alfa [AF_CC]) in Children with Hemophilia A") listed as an additional pharmacovigilance activity in the Risk Management Plan (RMP; MEA 116). The RMP version 13.0 has also been submitted.

In addition, the SmPC is being brought in line with the revised guidelines on core SmPC for human plasma derived and recombinant coagulation factor VIII products (Revision 3) in sections 4.2 Posology and Method of Administration, 4.4 Special warnings and special precautions for use, 4.8 Undesirable effects and 5.1 Pharmacodynamic effects."

Request for Supplementary Information adopted on 29.05.2019.

Request for supplementary information adopted with a specific timetable.

**Tecentriq - atezolizumab -
EMA/H/C/004143/II/0024**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of sections 4.2, 4.4, and 4.8 of the SmPC regarding the risk of immune-related myositis identified during a comprehensive analysis of patients treated with Tecentriq. The additional risk minimisations in Annex 2D, the Package Leaflet and the RMP (final version v11.1) are updated accordingly."

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Opinion adopted on 29.05.2019.

Venclyxto - venetoclax - EMEA/H/C/004106/II/0020, Orphan
AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Eva Jirsová, "Update of sections 4.2 and 5.2 of
the SmPC in order to modify posology
recommendations in patients with severe hepatic
impairment and to reflect the final results of
study M15-342 (A Study to Evaluate the Safety
and Pharmacokinetics of a Single Dose of
Venetoclax in Female Subjects with Mild,
Moderate, or Severe Hepatic Impairment) listed
as a category 3 study in the RMP; the Package
Leaflet is updated accordingly. The RMP version
3.4 has also been submitted."
Opinion adopted on 29.05.2019.
Request for Supplementary Information adopted
on 28.02.2019.

Positive Opinion adopted by consensus on
29.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

**Xiapex - collagenase clostridium
histolyticum - EMEA/H/C/002048/II/0107**
Swedish Orphan Biovitrum AB (publ),
Rapporteur: Janet Koenig, PRAC Rapporteur:
Martin Huber, "Update of sections 4.4 and 5.1 of
the SmPC to update the efficacy and safety
information following the final results from study
AUX-CC-810: Long-term Safety, Curvature
Deformity, Characterization, and
Immunogenicity over time in Subjects Previously
Treated with AA4500 for Peyronie's Disease in
Studies AUX-CC-802, AUX-CC-803,
AUC-X-CC-804, and AUX-CC-806; listed as a
category 3 study in the RMP. The RMP version
14.1 has also been approved.
In addition, the Marketing authorisation holder
took the opportunity to introduce minor editorial
changes to SmPC and Package Leaflet."
Opinion adopted on 29.05.2019.
Request for Supplementary Information adopted
on 28.03.2019.

Positive Opinion adopted by consensus on
29.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

**WS1490
IKERVIS-EMEA/H/C/002066/WS1490/
0014
Verkazia-EMEA/H/C/004411/WS1490/
0001**
Santen Oy, Lead Rapporteur: Peter Kiely, Lead
PRAC Rapporteur: Jan Neuhauser, "Submission
of an updated RMP version 7.2 in order to
implement RMP revision 2 template, as a

Positive Opinion adopted by consensus on
29.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

consequence list of safety concerns have been updated. The milestones for VERKAZIA PASS have also been updated.

In addition, the MAH proposed to align IKERVIS SmPC section 4.4 on concomitant therapy and effects on immune system with VERKAZIA SmPC in order to harmonize the routine risk minimization measures for both products. As a result of assessment SmPC section 4.3 has been updated for IKERVIS and VERKAZIA products to include new contraindication: Ocular or peri-ocular malignancies or premalignant conditions.

The MAH took this opportunity to implement the latest QRD template and the safety features for IKERVIS."

Opinion adopted on 29.05.2019.

Request for Supplementary Information adopted on 11.04.2019, 14.02.2019.

WS1582

Actraphane-EMEA/H/C/000427/WS1582/0076

Actrapid-EMEA/H/C/000424/WS1582/0070

Insulatard-EMEA/H/C/000441/WS1582/0073

Mixtard-EMEA/H/C/000428/WS1582/0077

Protaphane-EMEA/H/C/000442/WS1582/0072

Novo Nordisk A/S, Lead Rapporteur: Sinan B. Sarac, Lead PRAC Rapporteur: Hans Christian Siersted, "To update the Human Insulin RMP to version 3.0 in order to reclassify the risk of 'Medication errors' (including human error-related medication errors) from an important potential risk to an important identified risk following a Pharmacovigilance Risk Assessment Committee (PRAC) request (EMEA/H/C/PSUSA/00001753/201710) and in accordance with the Good practice guide on risk minimisation and prevention of medication errors, issued by the PRAC in 2015.

Furthermore, in accordance with the updated GVP Module V guidance on RMPs, the Worksharing Applicant (WSA) proposed to remove this risk as it is fully characterised and managed through routine pharmacovigilance and no additional pharmacovigilance activities or additional risk minimisation measures are

Request for supplementary information adopted with a specific timetable.

planned or being currently undertaken. Information regarding the avoidance of accidental mix-ups/medication errors is included in the PIL for the concerned products. In consequence, section 4.4 of the SmPC was updated in order to add a warning on accidental mix-ups/medication.

Additionally, the WSA took the opportunity include minor updates to Annex IIIA to bring the PI in line with the latest QRD template version." Request for Supplementary Information adopted on 16.05.2019.

WS1599

Rixathon-EMEA/H/C/003903/WS1599/0020

Riximyo-EMEA/H/C/004729/WS1599/0020

Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Anette Kirstine Stark, "Submission of the final report from study (GP13-301) listed as a category 3 study in the RMP. This is a randomized, controlled double-blind Phase III trial to compare the efficacy, safety and pharmacokinetics of GP2013 plus cyclophosphamide, vincristine, prednisone vs. MabThera plus cyclophosphamide, vincristine, prednisone, followed by GP2013 or MabThera maintenance therapy in patients with previously untreated advanced stage follicular lymphoma. The RMP version 4.0 has also been submitted." Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

B.5.4. PRAC assessed procedures

PRAC Led

Bydureon - exenatide - EMEA/H/C/002020/II/0059

AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final CSR for Study H80-MC-B016; a modified Prescription-Event Monitoring Program (Modified PEM) to be conducted in the UK, enrolling patients with Type 2 diabetes mellitus, to quantify the incidence of acute pancreatitis in the first 12 months after initiating treatment with prescription exenatide once weekly. An updated RMP version 33 was provided as part of the

Request for supplementary information adopted with a specific timetable.

application. The provision of the final CSR addresses Post-authorisation Measure MEA 010.5.”

Request for Supplementary Information adopted on 16.05.2019.

PRAC Led

Cimzia - certolizumab pegol - EMEA/H/C/001037/II/0074/G

UCB Pharma S.A., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “Submission of the final report from studies (RA0021 and RA005) listed as a category 3 studies in the RMP. Study RA0021 (ARTIS registry) is to provide short- and long-term safety data from the use of certolizumab pegol (CZP) in Sweden for rheumatoid arthritis (RA) patients. Study RA005 (NBD registry) is to obtain safety and outcome data on RA patients receiving CZP and other RA treatments. In addition, the MAH submitted interim results for two ongoing registries studies (RA0020/RABBIT and RA0022/BSRBR). Study RA0020/RABBIT is a German long-term observation of biologics/DMARD in RA. Study RA0022/BSRBR is a longitudinal observational study of patients with RA treated with biologic agents, and prospective surveillance study for adverse events.”

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 17.01.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

Firazyr - icanitibant - EMEA/H/C/000899/II/0047, Orphan

Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “Update of Risk Management Plan (RMP) in order to reflect the finalisation of the paediatric study HGT-FIR-086, update the main safety concerns following results of the paediatric study HGT-FIR-086 and remove study HGT-FIR-086 as an additional PV activity. In addition the RMP was reformatted to comply with the requirements of the new EU RMP template.

The requested variation proposed amendments to the Risk Management Plan (RMP).”

Opinion adopted on 16.05.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

<p>PRAC Led</p> <p>Forsteo - teriparatide - EMEA/H/C/000425/II/0050/G</p> <p>Eli Lilly Nederland B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final study reports of the European Union (EU) components of two post-authorisation safety studies (PASS); Study B3DMC-GHBX(2.2) and Study B3D-MC-GHBX(2.3b) both US population-based comparative cohort studies undertaken to evaluate a potential association between teriparatide and adult Osteosarcoma. An updated RMP version 7.0 was submitted as part of the application."</p> <p>Opinion adopted on 16.05.2019.</p> <p>Request for Supplementary Information adopted on 14.02.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p>Gardasil - human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed) - EMEA/H/C/000703/II/0081</p> <p>MSD Vaccins, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Update of the RMP to version 14.0 to update the list of safety concerns by removing the important identified risks syncope with fall resulting in injury, the important potential risks: viral type replacement and convulsion, and the missing information: immunogenicity, unanticipated safety signals and long-term safety, and in order to incorporate information from completed category 3 post-approval measure and scientific information on the safety profile of the qHPV vaccine."</p> <p>Opinion adopted on 16.05.2019.</p> <p>Request for Supplementary Information adopted on 14.03.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p>Hemangioliol - propranolol - EMEA/H/C/002621/II/0019</p> <p>PIERRE FABRE DERMATOLOGIE, Rapporteur: Joseph Emmerich, PRAC Rapporteur: Eva A. Segovia, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, "Update of Package Leaflet in order to strengthen the warning on Hypoglycemia and Bronchospasm following completion of Drug Utilisation Study (DUS) performed in Germany and France to evaluate off-label use and</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

effectiveness of RMM in a real-life clinical setting (MEA 002). In additions editorial changes have been introduced in section 4.4 of the SmPC as well as changes in the PL in accordance with QRD template 10.0. RMP version 3.1 has been submitted in order to updates the additional RMMs as a consequence of the results of the DUS.”

Request for Supplementary Information adopted on 16.05.2019, 14.02.2019.

PRAC Led

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0068**

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “C.I.11: Submission of an updated RMP version 23.1 in order to discuss the effectiveness of the educational materials put in place for Keytruda at the time of the initial marketing authorization and to provide a proposal to update these materials as well as to revise the safety specification as requested by PRAC during PSUSA/00010403/2018 procedure.”

Request for Supplementary Information adopted on 16.05.2019, 14.03.2019.

Request for supplementary information adopted with a specific timetable.

PRAC Led

**Kovaltry - octocog alfa -
EMA/H/C/003825/II/0022**

Bayer AG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Update of the RMP version 2.0 in line with the GVP revision 2 and the new RMP template.”
Opinion adopted on 16.05.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

**Neuraceq - florbetaben (18f) -
EMA/H/C/002553/II/0028**

Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “Submission of the final report from non-interventional PASS study FBB-01_02_13 listed as a category 3 study in the RMP. This is a prospective observational study to assess effectiveness of the training and risk minimisation measures recommended for the usage of the diagnostic agent NeuraCeq in the post-authorisation clinical situation.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

The RMP version 3.9 has also been submitted.”
Opinion adopted on 16.05.2019.

PRAC Led

ProQuad - measles, mumps, rubella and varicella vaccine (live) -

EMA/H/C/000622/II/0134

MSD Vaccins, Rapporteur: Jan Mueller-Berghaus,
PRAC Rapporteur: Brigitte Keller-Stanislawski,
PRAC-CHMP liaison: Jan Mueller-Berghaus,
“Submission of an updated RMP (version 6.1) in order to adhere to Version 2 of the RMP template.

As a consequence, the following changes are carried out:

- Removal of the important identified risks febrile seizure, fever, measles-like rash, and thrombocytopenia and the addition of disseminated disease caused by Oka/Merck vaccine virus strain.
- The important potential risks varicella-like or herpes zoster-like rashes, potential central nervous system events, potential transmission of varicella vaccine virus strain, exposure of immunocompromised individuals, hypersensitivity including anaphylaxis and injection-site reactions are also removed.
- Additionally, secondary transmission of Oka/Merck vaccine virus strain in susceptible high-risk individuals leading to severe clinical consequences is included.
- The important missing information ‘categories exposure during pregnancy’ and ‘safety and immunogenicity in patients less than 9 months’ of age is also removed.”

Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

PRAC Led

Sutent - sunitinib -

EMA/H/C/000687/II/0073

Pfizer Europe MA EEIG, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Daniela Melchiorri, “C.I.11: Submission of an updated RMP version 17 in order to review the list of safety concerns to make it more risk proportionate based on any available safety data. The updates are in line with the new GVP Module V (Rev 2) guidelines and new RMP template.”

Request for Supplementary Information adopted on 16.05.2019, 17.01.2019.

Request for supplementary information adopted with a specific timetable.

PRAC Led
Vectibix - panitumumab -
EMA/H/C/000741/II/0093
Amgen Europe B.V., Rapporteur: Bjorg Bolstad,
PRAC Rapporteur: David Olsen, PRAC-CHMP
liaison: Bjorg Bolstad, "Submission of RMP
version 23 for panitumumab to align the
important identified and potential risks and
missing information with the EMA guideline on
Good Pharmacovigilance Practices Module V
(Rev. 2). As a result Annex II has been updated.
The MAH is taking the opportunity to update
sections 4.2 and 4.4 to include the table on dose
modification previously located in the section 4.4.
The section 4.4 is also updated to implement the
latest excipient guideline recommendation on
sodium content. In addition, minor corrections
are introduced in the section 4.8 of the SmPC and
in the list of the local representatives."
Request for Supplementary Information adopted
on 16.05.2019.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
Votriant - pazopanib -
EMA/H/C/001141/II/0054
Novartis Europharm Limited, Rapporteur: Sinan
B. Sarac, PRAC Rapporteur: Anette Kirstine
Stark, PRAC-CHMP liaison: Sinan B. Sarac,
"Submission of an updated RMP version 17.0 in
order to postpone CSR submission for
"COMPARZ" study and its substudy, to reflect
PRAC recommendations for additional
assessments of some risks, to revise the list of
safety concerns, and to adapt to GVP template."
Request for Supplementary Information adopted
on 16.05.2019.

Request for supplementary information adopted
with a specific timetable.

PRAC Led
Zydelig - idelalisib -
EMA/H/C/003843/II/0046
Gilead Sciences Ireland UC, Rapporteur: Filip
Josephson, PRAC Rapporteur: Martin Huber,
PRAC-CHMP liaison: Martina Weise, "Submission
of the clinical study report for study
GS-EU-313-4226, A Cross-Sectional
Post-Authorization Safety Study to Assess
Healthcare Provider Awareness of Risks
Associated with Zydelig in the European Union;
this is a category 3 PASS study to assess the
effectiveness of additional risk minimization
measures by determining the level of knowledge
of haematologists and oncologists (who manage

Positive Opinion adopted by consensus on
16.05.2019. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

patients with CLL or FL) about the infection risks associated with Zydelig treatment and the corresponding recommendation to minimize these risks as outlined in the SmPC and communicated in the direct healthcare professional communication (DHPC). This is to fulfill RMP post-authorisation measure MEA 016.”
Opinion adopted on 16.05.2019.
Request for Supplementary Information adopted on 14.03.2019.

PRAC Led

WS1536

Levitra-EMEA/H/C/000475/WS1536/0064

Vivanza-EMEA/H/C/000488/WS1536/

0060

Bayer AG, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro, “Submission of the final clinical study report of study 12912 a non-interventional PASS (category 3 study) to investigate the NAION (Non-arteritic anterior ischemic optic neuropathy) risk associated with PDE5 inhibitors together with a consequential update of the RMP.”

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 14.03.2019.

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led

WS1543

Ultibro Breezhaler-EMEA/H/C/002679/

WS1543/0029

Ulnar Breezhaler-EMEA/H/C/003875/

WS1543/0029

Xoterna Breezhaler-EMEA/H/C/003755/

WS1543/0033

Novartis Europharm Limited, Lead Rapporteur: Mark Ainsworth, Lead PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, “Submission of the final study report of the Category I Post-Authorisation Safety Study (PASS) COVA149A2402 (Multinational database cohort study in Europe in COPD patients, to assess the incidence rates and hazard ratios of various safety outcomes in new users of indacaterol/glycopyrronium compared to new users of comparator drugs (at the drug-class level).

The Product Information has been updated by the removal of the black triangle and amendments in

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Annex II.D (Conditions or restrictions with regard to the safe and effective use of the medicinal product). The RMP version 5.0 has been submitted accordingly.”

Opinion adopted on 16.05.2019.

Request for Supplementary Information adopted on 14.03.2019.

PRAC Led

WS1581

Rasilez-EMEA/H/C/000780/

WS1581/0123

Rasilez HCT-EMEA/H/C/000964/WS1581/0093

Noden Pharma DAC, Lead Rapporteur: Daniela Melchiorri, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Daniela Melchiorri, “Submission of an updated RMP version 14 in order to update the template in line with GVP Module V Rev2 required, add new important potential risk of non-melanoma skin cancer (related to Rasilez HCT only), and remove several important risks and missing information items as per PRAC endorsement of PSUR 12.”

Request for supplementary information adopted with a specific timetable.

PRAC Led

WS1586

Anoro Ellipta-EMEA/H/C/002751/

WS1586/0028

Laventair Ellipta-EMEA/H/C/003754/

WS1586/0031

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Jayne Crowe, Lead PRAC Rapporteur: Amelia Cupelli, PRAC-CHMP liaison: Daniela Melchiorri, “Submission of an updated RMP version 8.0 following Annual Renewal Procedure (EMEA/H/C/4002751/R/0022/ EMEA/H/C/003754/R/0025) commitments to remove the important identified risks of Hypersensitivity and Paradoxical bronchospasm (which may be life-threatening) from the list of safety concerns and to update all relevant sections of the RMP accordingly.

MAH is also proposing to remove some additional risks (narrow angle glaucoma, Bladder outflow obstruction and urinary retention, Safety in pregnancy and lactation, Safety in long-term use, Safety in severe hepatic impairment), which have not been previously discussed with EMA.”

Request for Supplementary Information adopted on 16.05.2019.

Letter from the applicant dated 22.05.2019

Request for supplementary information adopted with a specific timetable.

requesting a clock stop extension. **For information.**

PRAC Led
WS1596
Humalog-EMEA/H/C/000088/WS1596/0172
Liprolog-EMEA/H/C/000393/WS1596/0133

Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Submission of the final report from on-going review of adverse drug events related to Humalog MEA/028 and Liprolog MEA/021, listed as a category 3 study in the RMP. This is a post approval safety surveillance programme for lot-specific adverse event review to evaluate any potential change in frequency of hypersensitivity, immunogenicity, and lack of drug effect (LODE) events for insulin lispro synthesized via new manufacturing process."

Opinion adopted on 14.06.2019.

Request for Supplementary Information adopted on 16.05.2019.

Request for supplementary information adopted with a specific timetable.

PRAC Led
WS1603
Pregabalin Mylan-EMEA/H/C/004078/WS1603/0013
Pregabalin Mylan Pharma-EMEA/H/C/003962/WS1603/0011

Mylan S.A.S, Generic, Generic of Lyrica, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "To align the RMP with the originator (updated as part of procedure EMEA/H/C/000546/WS1364/0092). In addition the RMP is updated to the latest template and is also harmonised for all pregabalin marketing authorisations procedures for which Mylan has an approved RMP."

Request for supplementary information adopted with a specific timetable.

PRAC Led
WS1608
Filgrastim Hexal-EMEA/H/C/000918/WS1608/0049
Zarzio-EMEA/H/C/000917/WS1608/0050

Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, "The scope of the variation application is to align on the due dates and deliverables for the post-authorization measure,

Request for supplementary information adopted with a specific timetable.

MEA007. The due date is extended from Dec 2019 to March 2020, to combine the annual safety report (ASR) with the 5-year interim clinical study report (CSR) in 2020 and the final CSR in 2024 and for the MEA to cover the entire duration of study EP06-501.”

Request for Supplementary Information adopted on 16.05.2019.

B.5.5. CHMP-CAT assessed procedures

Spherox - spheroids of human autologous matrix-associated chondrocytes -

EMA/H/C/002736/II/0005/G, ATMP

CO.DON AG, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder, “Update of the product information to reflect the study results of the 36-month follow up data for trial cod 16 HS 13 and the final study report with 60-month follow-up data for trial cod 16 HS 14.

Study cod 16 HS 13, is a Prospective, randomised, open label, multicentre Phase-III clinical trial to compare the efficacy and safety of the treatment with the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) with microfracture in subjects with cartilage defects of the knee with a defect size between 1 and 4 cm².

Study cod 16 HS 14, is a Prospective, randomised, open label, multicentre Phase-II clinical trial to investigate the efficacy and safety of the treatment of large defects (4-10 cm²) with three different doses of the autologous chondrocyte transplantation product co.don chondrosphere (ACT3D-CS) in subjects with cartilage defects of the knee.”

Request for Supplementary Information adopted on 24.05.2019.

Request for supplementary information adopted with a specific timetable.

YESCARTA - axicabtagene ciloleucel - EMA/H/C/004480/II/0007, Orphan, ATMP

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 24.05.2019.

Request for supplementary information adopted with a specific timetable.

B.5.6. CHMP-PRAC-CAT assessed procedures

Zalmoxis - nalotimagene carmaleucel -

Request for supplementary information adopted

EMA/H/C/002801/II/0016, Orphan, ATMP

MolMed S.p.A, Rapporteur: Carla Herberts, Co-Rapporteur: Sol Ruiz, CHMP Coordinator: Paula Boudewina van Hennik and Maria Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski, "The MAH is proposing to terminate the study TK008 (specific obligation for the CMA) and replace it with study TK013"
Request for Supplementary Information adopted on 24.05.2019.

with a specific timetable.

B.5.7. PRAC assessed ATMP procedures

PRAC Led

Alofisel - darvadstrocel - EMA/H/C/004258/II/0006, Orphan, ATMP

Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, CHMP Coordinator: Kristina Dunder, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of an updated RMP version 7 in order to propose replacement of the observational PASS study (Category 3) with two separate studies: a long-term safety extension of the ADMIRE-CD II study and a retreatment PASS. The European multi-database linkage study is added for the assessment of the potential risk of tumorigenicity."
Opinion adopted on 29.05.2019, 24.05.2019.

Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS1541

**Abasaglar-EMA/H/C/002835/WS1541/0025
Humalog-EMA/H/C/000088/WS1541/0173
Liprolog-EMA/H/C/000393/WS1541/0134**

Eli Lilly Nederland B.V., Lead Rapporteur: Kristina Dunder
Request for Supplementary Information adopted on 23.05.2019.

Request for supplementary information adopted with a specific timetable.

WS1560

**Renvela-EMA/H/C/000993/WS1560/0048
Sevelamer carbonate Winthrop-EMA/H/C/**

Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

<p>003971/WS1560/0019</p> <p>Genzyme Europe BV, Lead Rapporteur: Bart Van der Schueren, "To introduce new presentation with new dosing spoon for Renvela (EU/1/09/521/009) and Sevelamer carbonate Winthrop (EU/1/14/952/006) 0.8 g powder for oral suspension sachet.</p> <p>This variation fulfils commitment to develop a suitable device which would allow the accurate administration of the minimum 0.4g increments of sevelamer carbonate, that was undertaken during the line extension procedures.</p> <p>In addition, the MAH took the opportunity to introduce editorial changes in the product information."</p> <p>Opinion adopted on 16.05.2019.</p> <p>Request for Supplementary Information adopted on 14.03.2019.</p>	<p>recommendation.</p>
<p>WS1562/G</p> <p>Aflunov-EMEA/H/C/002094/WS1562/0047/G</p> <p>Foclivia-EMEA/H/C/001208/WS1562/0042/G</p> <p>Seqirus S.r.l, Lead Rapporteur: Daniela Melchiorri</p> <p>Opinion adopted on 02.05.2019.</p> <p>Request for Supplementary Information adopted on 28.03.2019.</p>	<p>Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1572</p> <p>Juluca-EMEA/H/C/004427/WS1572/0014</p> <p>Tivicay-EMEA/H/C/002753/WS1572/0049</p> <p>ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig</p> <p>Opinion adopted on 16.05.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1576/G</p> <p>Blitzima-EMEA/H/C/004723/WS1576/0021/G</p> <p>Ritemvia-EMEA/H/C/004725/WS1576/0021/G</p> <p>Rituzena-EMEA/H/C/004724/WS1576/0022/G</p> <p>Truxima-EMEA/H/C/004112/WS1576/0023/G</p> <p>Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz</p> <p>Opinion adopted on 02.05.2019.</p>	<p>Positive Opinion adopted by consensus on 02.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1579</p> <p>Axura-EMEA/H/C/000378/WS1579/0081</p> <p>Memantine Merz-EMEA/H/C/002711/</p>	<p>Positive Opinion adopted by consensus on 29.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP</p>

<p>WS1579/0017 Merz Pharmaceuticals GmbH, Lead Rapporteur: Maria Concepcion Prieto Yerro Opinion adopted on 29.05.2019. Request for Supplementary Information adopted on 26.04.2019.</p>	<p>recommendation.</p>
<p>WS1583 M-M-RVAXPRO-EMEA/H/C/000604/ WS1583/0094 ProQuad-EMEA/H/C/000622/WS1583/ 0133 MSD Vaccins, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 16.05.2019.</p>	<p>Positive Opinion adopted by consensus on 16.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1590 Segluromet-EMEA/H/C/004314/WS1590/ 0006 Steglatro-EMEA/H/C/004315/WS1590/ 0006 Steglujan-EMEA/H/C/004313/WS1590/ 0008 Merck Sharp & Dohme B.V., Lead Rapporteur: Kristina Dunder, "To update sections 4.4 and 4.8 of the SmPC in order to implement the PRAC Recommendation on the signal of Fournier's gangrene for SGLT-2 inhibitors. The Package leaflet is being updated accordingly. In addition, the MAH is proposing an additional text the package leaflet to include the frequency of Fournier's gangrene, in alignment with the SmPC." Opinion adopted on 23.05.2019.</p>	<p>Positive Opinion adopted by consensus on 23.05.2019. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>WS1595 Kalydeco-EMEA/H/C/002494/WS1595/ 0078 Symkevi-EMEA/H/C/004682/WS1595/ 0009 Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, "To provide a final Environmental Risk Assessment report." Request for Supplementary Information adopted on 16.05.2019.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>B.5.9. Information on withdrawn type II variation / WS procedure</p>	
<p>Yervoy - ipilimumab -</p>	<p>The MAH withdrew the procedure on 10.05.2019.</p>

EMA/H/C/002213/II/0063

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Paula Boudewina van Hennik, PRAC Rapporteur:
Menno van der Elst, "Update of sections 4.4 and 4.8 of the SmPC and of annex II in order to add safety information regarding Graft Versus Host Disease (GVHD) in allogeneic hematopoietic stem cell transplant (HSCT) recipients after treatment with ipilimumab. The update is based on a review of post-marketing data. The Package Leaflet and the RMP (version 25.0) is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some editorial changes in the PI and RMP and to include some changes in the RMP due to previous procedures."

Request for Supplementary Information adopted on 17.01.2019.

Withdrawal request submitted on 10.05.2019.

Zejula - niraparib -**EMA/H/C/004249/II/0006, Orphan**

Tesaro Bio Netherlands B.V., Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Jan Neuhauser, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to optimise the starting dose of niraparib and clarify dose modification information, modify the existing warning on haematologic adverse reactions, amend the description of thrombocytopenia and amend existing efficacy and pharmacokinetics information, respectively. The changes are based on the integrated Population clinical report that contains information from the completed Phase 3 NOVA, study submitted as part of the initial MAA, as well as supportive information from the ongoing phase 2 PR-30-5020-C (QUADRA) and phase 1 / 2 300-PN-162-01-001 (TOPACIO) studies. The update of the SmPC posology is based on exposure response study reports to propose alternative dosing strategies that aim to reduce Grade 3/4 thrombocytopenia; the Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted to reflect the new EU RMP format. Furthermore, the core sections of the RMP have been updated to: align with niraparib PSUR 1, reflect post-authorization experience, inclusion of embolic and thrombotic events as important potential risks and to optimize the starting dose of niraparib to reduce adverse events."

The MAH withdrew the procedure on 26.04.2019.

Request for Supplementary Information adopted on 28.03.2019, 29.11.2018.

Withdrawal request submitted on 26.04.2019

B.5.10. Information on type II variation / WS procedure with revised timetable

PRAC Led

The CHMP adopted an updated timetable

Cerdelga - eliglustat -

EMA/H/C/003724/II/0020, Orphan

Genzyme Europe BV, PRAC Rapporteur: Eva A. Segovia, "Submission of the final report from study ELIGLC06912 listed as a category 3 study in the RMP (MEA006). This is a Drug Utilization Study of Eliglustat in the United States (US) Population Using MarketScan Database and the International Collaborative Gaucher Group Registry. Consequently, submission of an updated RMP version 6 in order to reflect the submission of the final data for study ELIGLC06912. In addition, RMP version 6.0 has been aligned with the Guideline on GVP - Module V, revision 2 and the related new EU RMP template has been implemented."

Request for Supplementary Information adopted on 14.03.2019.

WS1524

HyQvia-EMA/H/C/002491/WS1524/0048

Kiovig-EMA/H/C/000628/WS1524/0090

Baxter AG, Lead Rapporteur: Jan

Mueller-Berghaus

Request for Supplementary Information adopted on 14.03.2019.

Request for an extension to the clock stop to respond to the Request for Supplementary Information adopted in March 2019.

The CHMP agreed to the request for an extension to the clock stop and adopted an updated timetable.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

indacaterol / mometasone furoate -

EMA/H/C/005067

treatment of asthma

azacitidine - EMA/H/C/005300

Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

cabazitaxel - EMA/H/C/005178

treatment of adult patients with metastatic castration resistant prostate cancer previously

treated with a docetaxel-containing regimen

glasdegib - EMEA/H/C/004878, Orphan

Pfizer Europe MA EEIG, treatment of newly diagnosed de novo or secondary acute myeloid leukaemia

doxorubicin - EMEA/H/C/005194

treatment of breast cancer, ovarian cancer, progressive multiple myeloma and AIDS-related Kaposi's sarcoma

indacaterol / glycopyrronium / mometasone - EMEA/H/C/005061

treatment of asthma and to reduce asthma exacerbations

fingolimod - EMEA/H/C/005191

treatment of multiple sclerosis

fingolimod - EMEA/H/C/005282

treatment of multiple sclerosis

lacosamide - EMEA/H/C/005243

treatment of epilepsy

rituximab - EMEA/H/C/005387

treatment of Non-Hodgkin's Lymphoma (NHL), chronic lymphocytic leukaemia (CLL)

teriparatide - EMEA/H/C/005087

treatment of osteoporosis

teriparatide - EMEA/H/C/005388

treatment of osteoporosis

luspatercept - EMEA/H/C/004444, Orphan

Celgene Europe BV, - treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS)-associated anaemia; - the treatment of adult patients with beta-thalassaemia (β -thalassaemia)-associated anaemia who require RBC transfusions

semaglutide - EMEA/H/C/004953

treatment of type 2 diabetes mellitus

isatuximab - EMEA/H/C/004977, Orphan

sanofi-aventis groupe, For the treatment of patients with multiple myeloma (MM)

lidocaine / prilocaine - EMEA/H/C/005298

treatment of primary premature ejaculation

trastuzumab - EMEA/H/C/005066

treatment of metastatic and early breast cancer

and metastatic gastric cancer (MGC)

deferiprone - EMEA/H/C/005004, Orphan

Apotex B.V., treatment of neurodegeneration
with brain iron accumulation

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

Kymriah - tisagenlecleucel -

EMEA/H/C/004090/X/0010, Orphan, ATMP

Novartis Europharm Limited, Rapporteur: Rune
Kjeken, Co-Rapporteur: Dariusz Sladowski,
CHMP Coordinator: Ingrid Wang and Ewa
Balkowiec Iskra

**B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables:
for information**

arsenic trioxide - EMEA/H/C/005175

treatment of relapsed acute promyelocytic
leukaemia (APL)

List of Questions adopted on 26.04.2019.

bortezomib - EMEA/H/C/005074

treatment of multiple myeloma

List of Questions adopted on 31.01.2019.

tagraxofusp - EMEA/H/C/005031, Orphan

TMC Pharma (EU) Limited, treatment of adult
patients with blastic plasmacytoid dendritic cell
neoplasm (BPDCN)

List of Questions adopted on 24.04.2019.

fostamatinib - EMEA/H/C/005012

indicated for the treatment of thrombocytopenia

List of Questions adopted on 31.01.2019.

emapalumab - EMEA/H/C/004386, Orphan

Novimmune B.V., treatment of paediatric
patients with primary haemophagocytic
lymphohistiocytosis (HLH)

List of Questions adopted on 13.12.2018.

Imraldi - adalimumab -

EMEA/H/C/004279/X/0019/G

Samsung Bioepis NL B.V., Rapporteur: Outi
Mäki-Ikola, PRAC Rapporteur: Ulla Wändel
Liminga, "Extension application to introduce a
new presentation of 40 mg/0.8 ml solution for
injection in a vial, to allow the administration to
paediatric patients requiring less than a full 40mg
dose.

C.I.z - To update the Product Information for the

pre-filled syringe (EU/1/17/1216/001-004) and pre-filled pen (EU/1/17/1216/005-008) presentations in line with the dosage regimen changes introduced with the extension application.

The RMP (version 3.0) is updated in accordance. In addition, the applicant took the opportunity to implement minor editorial changes " List of Questions adopted on 28.03.2019.

clofarabine - EMEA/H/C/005039

treatment of acute lymphoblastic leukaemia
List of Questions adopted on 31.01.2019.

Kalydeco - ivacaftor -

EMEA/H/C/002494/X/0075/G, Orphan

Vertex Pharmaceuticals (Ireland) Limited,
Rapporteur: Maria Concepcion Prieto Yerro, PRAC
Rapporteur: Maria del Pilar Rayon, "Extension application to add a new strength of 25 mg granules in sachet in the treatment of cystic fibrosis in children aged 6 to less than 12 months old.

C.I.4 - To update sections 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC, and sections 2 and 3 of the PL for the 150 mg film-coated tablet presentations to bring it in line with the new dosage form (25 mg granules), which supports the extension of indication for children aged 6 to 12 months old. The RMP (version 8.3) is updated in accordance. In addition, the MAH took the opportunity to implement minor updates in the Product Information."

List of Questions adopted on 26.04.2019.

omadacycline tosilate - EMEA/H/C/004715

treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) in adults
List of Questions adopted on 31.01.2019.

osilodrostat - EMEA/H/C/004821, Orphan

Novartis Europharm Limited, treatment of Cushing's syndrome
List of Questions adopted on 28.03.2019.

polatuzumab vedotin - EMEA/H/C/004870, Orphan

Roche Registration GmbH, Treatment of mature B cell lymphomas
List of Questions adopted on 24.04.2019.

Remsima - infliximab -

EMEA/H/C/002576/X/0062

Celltrion Healthcare Hungary Kft., Rapporteur:
Outi Mäki-Ikola, Co-Rapporteur: Kristina Dunder,
PRAC Rapporteur: Kimmo Jaakkola, "Extension
application to introduce a new pharmaceutical
form (solution for injection), a new strength (120
mg) and a new route of administration
(subcutaneous use).

The RMP (version 9.1) is updated in accordance."

List of Questions adopted on 28.03.2019.

rituximab - EMEA/H/C/004807

treatment of Non-Hodgkin's lymphoma (NHL),
chronic lymphocytic leukaemia (CLL) and
rheumatoid arthritis

List of Questions adopted on 18.10.2018.

netarsudil - EMEA/H/C/004583

indicated for the reduction of elevated intraocular
pressure (IOP) in adults with open-angle
glaucoma or ocular hypertension

List of Questions adopted on 31.01.2019.

esketamine - EMEA/H/C/004535

treatment-resistant depression

List of Questions adopted on 28.02.2019.

solriamfetol - EMEA/H/C/004893

is indicated to improve wakefulness in patients
with narcolepsy or obstructive sleep apnoea

List of Questions adopted on 28.03.2019.

quizartinib - EMEA/H/C/004468, Orphan

Daiichi Sankyo Europe GmbH, treatment of acute
myeloid leukaemia

List of Questions adopted on 29.01.2019.

plazomicin - EMEA/H/C/004457

treatment of Complicated urinary tract infection
(cUTI), including pyelonephritis; treatment of
Bloodstream infection (BSI); treatment of
infections due to Enterobacteriaceae

List of Questions adopted on 28.02.2019.

onasemnogene abeparvovec -**EMEA/H/C/004750, Orphan, ATMP**

AveXis Netherlands B.V., treatment of
treatment of spinal muscular atrophy (SMA)

List of Questions adopted on 22.02.2019.

B.6.4. Annual Re-assessments: timetables for adoption

Chenodeoxycholic acid Leadiant -**chenodeoxycholic acid -**

EMEA/H/C/004061/S/0010, Orphan

Leadiant GmbH, Rapporteur: Constantinos Markopoulos, PRAC Rapporteur: Adam Przybylkowski

Elaprase - idursulfase -**EMEA/H/C/000700/S/0080**

Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

Cerdelga - eliglustat -**EMEA/H/C/003724/R/0022, Orphan**

Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Martina Weise, PRAC Rapporteur: Eva A. Segovia

Exviera - dasabuvir -**EMEA/H/C/003837/R/0045**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Maria del Pilar Rayon

NINLARO - ixazomib -**EMEA/H/C/003844/R/0017, Orphan**

Takeda Pharma A/S, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Annika Folin

SCENESSE - afamelanotide -**EMEA/H/C/002548/R/0026, Orphan**

Clinuvel Europe Limited, Rapporteur: Janet Koenig, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Martin Huber

Senshio - ospemifene -**EMEA/H/C/002780/R/0028**

Shionogi B.V., Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Joseph Emmerich, PRAC Rapporteur: Kirsti Villikka

Sevelamer carbonate Winthrop - sevelamer carbonate - EMEA/H/C/003971/R/0022

Genzyme Europe BV, Rapporteur: Bart Van der Schueren, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Laurence de Fays

Tyverb - lapatinib -**EMEA/H/C/000795/R/0060**

Novartis Europharm Limited, Rapporteur: Filip Josephson, Co-Rapporteur: Bruno Sepodes,

PRAC Rapporteur: Annika Folin

**Vectibix - panitumumab -
EMA/H/C/000741/R/0094**

Amgen Europe B.V., Rapporteur: Bjorg Bolstad,
Co-Rapporteur: Constantinos Markopoulos, PRAC
Rapporteur: David Olsen

**Viekirax - ombitasvir / paritaprevir /
ritonavir - EMA/H/C/003839/R/0054**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Filip Josephson, Co-Rapporteur:
Johann Lodewijk Hillege, PRAC Rapporteur: Maria
del Pilar Rayon

**Xadago - safinamide -
EMA/H/C/002396/R/0032**

Zambon S.p.A., Rapporteur: Johann Lodewijk
Hillege, Co-Rapporteur: Agnes Gyurasics, PRAC
Rapporteur: Rhea Fitzgerald

**Xydalba - dalbavancin -
EMA/H/C/002840/R/0028**

Allergan Pharmaceuticals International Limited,
Rapporteur: Filip Josephson, Co-Rapporteur:
Bjorg Bolstad, PRAC Rapporteur: Rugile
Pilviniene

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

**Darzalex - daratumumab -
EMA/H/C/004077/II/0029, Orphan**

Janssen-Cilag International NV, Rapporteur:
Sinan B. Sarac, Co-Rapporteur: Jorge Camarero
Jiménez, PRAC Rapporteur: Marcia Sofia Sanches
de Castro Lopes Silva, "Extension of indication to
extend the existing therapeutic indication for
Darzalex (daratumumab) in combination with
lenalidomide and dexamethasone (Rd) for the
treatment of adult patients with newly diagnosed
multiple myeloma who are ineligible for
autologous stem cell transplant (ASCT); as a
consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and
5.2 of the SmPC are updated. The Package
Leaflet is updated in accordance. The RMP
(Version 6, Succession 1) has also been
submitted."

Darzalex - daratumumab -

EMA/H/C/004077/II/0030, Orphan

Janssen-Cilag International NV, Rapporteur:
Sinan B. Sarac, Co-Rapporteur: Jorge Camarero Jimenez, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Extension of indication to extend the existing therapeutic indication for DARZALEX (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT); as a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. The RMP (Version 6, Succession 1) has also been submitted."

Trulicity - dulaglutide -**EMA/H/C/002825/II/0040**

Eli Lilly Nederland B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Amelia Cupelli, "Extension of indication to include a new indication for Trulicity; "to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke), in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors without established cardiovascular disease, and in adults with type 2 diabetes mellitus with established cardiovascular disease."

The data supporting this new indication is derived from Study GBDJ (Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)); a single pivotal Phase 3 long-term cardiovascular outcomes study, which assessed the efficacy and safety of treatment with once-weekly injection of dulaglutide 1.5 mg when added to glucose-lowering regimen of patients with type 2 diabetes (T2D), compared to the addition of a once weekly placebo injection. This study is a post-authorisation measure (PAM) (MEA 004) included in the dulaglutide RMP.

As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are being updated and the Package Leaflet is updated accordingly.

In addition, the MAH is taking the opportunity to update the wording of the existing indication in section 4.1 of the SmPC and to implement a minor change in section 5.1 of the SmPC, in the glycaemic control summary subsection, based on the results from the dulaglutide study as add-on

to sodium-glucose co-transporter 2 inhibitor therapy which was assessed as part of II/25. An updated RMP version 3.1 was provided as part of the application."

Zavicefta - ceftazidime / avibactam -

EMA/H/C/004027/II/0015

Pfizer Ireland Pharmaceuticals, Rapporteur: Bjorg Bolstad, Co-Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Rugile Pilviniene, "Extension of indication to include paediatric patients aged 3 months to less than 18 years for Zavicefta (for the treatment of cIAI and cUTI), based on data from paediatric studies D4280C00014, C3591004 and C3591005 and the population PK modelling/simulation analyses (CAZ-MS-PED-01 and CAZ-MS-PED-02). As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2, 6.3 and 6.6 of the SmPC are updated in order to reflect this additional population, the paediatric posology, paediatric safety information, the description of the clinical trials and handling instructions for paediatric dosing. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct the sodium content to SmPC sections 2 and 4.4 and PL section 2 and the volumes of distribution of ceftazidime and avibactam in SmPC section 5.2. Furthermore, the MAH is also introducing a correction in the Czech SmPC to add missing values in the table in SmPC section 5.1. The RMP version 3.0 has also been submitted."

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Advate - octocog alfa -

EMA/H/C/000520/II/0100

Baxter AG, Rapporteur: Jan Mueller-Berghaus

AMGEVITA - adalimumab -

EMA/H/C/004212/II/0017

Amgen Europe B.V., Rapporteur: Kristina Dunder

Atazanavir Mylan - atazanavir -

EMA/H/C/004048/II/0012

Mylan S.A.S, Generic, Generic of Reyataz, Rapporteur: Bjorg Bolstad

Atriance - nelarabine -

EMA/H/C/000752/II/0047/G

Novartis Europharm Limited, Rapporteur: Sinan

B. Sarac

Cimzia - certolizumab pegol -

EMA/H/C/001037/II/0079/G

UCB Pharma S.A., Rapporteur: Kristina Dunder

Dupixent - dupilumab -

EMA/H/C/004390/II/0018/G

sanofi-aventis groupe, Rapporteur: Jan
Mueller-Berghaus

Erelzi - etanercept -

EMA/H/C/004192/II/0018

Sandoz GmbH, Rapporteur: Johann Lodewijk
Hillege

Eylea - aflibercept -

EMA/H/C/002392/II/0053

Bayer AG, Rapporteur: Alexandre Moreau

Inhixa - enoxaparin sodium -

EMA/H/C/004264/II/0048/G

Techdow Europe AB, Duplicate, Duplicate of
Thorinane, Rapporteur: Andrea Laslop

Kovaltry - octocog alfa -

EMA/H/C/003825/II/0023

Bayer AG, Rapporteur: Kristina Dunder

NovoRapid - insulin aspart -

EMA/H/C/000258/II/0128

Novo Nordisk A/S, Rapporteur: Kristina Dunder

Omnitrope - somatropin -

EMA/H/C/000607/II/0060

Sandoz GmbH, Rapporteur: Johann Lodewijk
Hillege

OPDIVO - nivolumab -

EMA/H/C/003985/II/0067/G

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Jorge Camarero Jiménez

Rebif - interferon beta-1a -

EMA/H/C/000136/II/0141

Merck Europe B.V., Rapporteur: Filip Josephson

Skyrizi - risankizumab -

EMA/H/C/004759/II/0002/G

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Peter Kiely

Voncento - human coagulation factor VIII /

human von willebrand factor -

EMA/H/C/002493/II/0041/G

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Amglidia - glibenclamide -

EMA/H/C/004379/II/0004, Orphan

Ammtek, Rapporteur: Martina Weise, "Update of sections 4.2 and 5.1 of the SmPC to reconcile posology instructions with the actual use of the product in clinical practice in order to avoid overdosing, to harmonise sections related to "Dosage adjustments and long-term treatment management" and remove reference to the off-label use of crushed tablets. This update is based on recently published literature, the ISPAD consensus guideline, and in line with the NEOGLI CSR.

In addition, the applicant took the opportunity to make editorial corrections."

Brintellix - vortioxetine -

EMA/H/C/002717/II/0022/G

H. Lundbeck A/S, Rapporteur: Bart Van der Schueren, "Update of sections 4.8 and 5.1 of the SmPC in order to describe effects of vortioxetine on treatment-emergent sexual dysfunction based on the outcome of 2 prospective clinical studies (Studies 318 and 4001).

Update of sections 4.4 and 5.2 of the SmPC in order to reflect the outcome of study 401 in subjects with severe hepatic impairment."

Cosentyx - secukinumab -

EMA/H/C/003729/II/0051

Novartis Europharm Limited, Rapporteur: Tuomo Lapveteläinen, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include additional dosing information for Ankylosing Spondylitis (AS) patients based on final results from study CAIN457F2314; this is a randomized, double-blind, double dummy, placebo controlled, parallel-group, Phase 3 multicenter study of secukinumab versus placebo to demonstrate efficacy at 16 weeks and to assess long-term efficacy up to Week 156 in patients with active AS; the Package Leaflet is updated accordingly."

CRYSVITA - burosumab -

EMA/H/C/004275/II/0004, Orphan

Kyowa Kirin Holdings B.V., Rapporteur: Kristina Dunder, "Update of sections 4.2, 4.8, 5.1 and 5.2

of the SmPC, to reflect the results of Study UX023-CL301, a phase III study undertaken to further assess the efficacy, safety and pharmacodynamics in paediatric patients aged 1-12 years with X-linked Hypophosphataemia (XLH). The provision of the final CSR addresses Specific Obligation 2 (ANX 002) and the requirements of article 46 of the paediatric regulation. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC to increase readability.”

**Deltyba - delamanid -
EMA/H/C/002552/II/0037, Orphan**

Otsuka Novel Products GmbH, Rapporteur:
Koenraad Norga, “x.C.I.13 MIC report as
amendment to CSR 242-09-213”

**Dengvaxia - dengue tetravalent vaccine
(live, attenuated) -**

EMA/H/C/004171/II/0003/G

Sanofi Pasteur, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Sonja Hrabcik, “C.I.13 grouping: Submission of the final report from studies CYD14 and CYD15 listed as category 3 studies in the RMP. These are the final results of the pivotal efficacy studies including amendments to long-term efficacy follow-up (to capture the full range of dengue disease in the study population prospectively i.e. return to active detection of all symptomatic dengue cases) and long-term safety monitoring. No changes to the PI or RMP identified are proposed at this stage. Minor updates of the RMP will follow.”

Keytruda - pembrolizumab -

EMA/H/C/003820/II/0075

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, “Update of section 5.1 of the SmPC in order to reflect the updated results from study KEYNOTE-010 listed as a category 3 study in the RMP with a data cutoff of 16 March 2018. Study KEYNOTE-010 is a controlled phase II/III trial that randomized a total of 1034 previously-treated subjects with advanced or metastatic NSCLC whose tumors express PD-L1 to receive pembrolizumab at 2 mg/kg Q3W or 10 mg/kg Q3W or docetaxel at 75 mg/m² Q3W. In addition, the MAH took the opportunity of this variation to include additional instructions in

section 4.5 of the SmPC to clarify the use of corticosteroids in subjects treated with pembrolizumab in combination with other chemotherapeutic agents. The Package Leaflet is updated accordingly.”

**Keytruda - pembrolizumab -
EMA/H/C/003820/II/0076**

Merck Sharp & Dohme B.V., Rapporteur: Daniela Melchiorri, “To update section 5.1 of the SmPC based on final results from study KEYNOTE-052 (KN052) listed as a PAES in Annex II; this is a single arm Phase II Clinical Trial of pembrolizumab in subjects with advanced/unresectable or metastatic urothelial cancer (1st line).”

**Kyntheum - brodalumab -
EMA/H/C/003959/II/0011**

LEO Pharma A/S, Rapporteur: Johann Lodewijk Hillege, “Update of section 5.1 of the SmPC “Mechanism of action” subsection with information about the cytokine IL-17C.”

**Kyprolis - carfilzomib -
EMA/H/C/003790/II/0038, Orphan**

Amgen Europe B.V., Rapporteur: Jorge Camarero Jiménez, “Update of section 6.6 of the SmPC with information regarding the handling and preparation of Kyprolis. The PL is updated accordingly.”

**MabThera - rituximab -
EMA/H/C/000165/II/0165**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, “Change in the posology section as 8 cycles of MabThera should be used in combination with 6-8 (previously 8) cycles of CHOP chemotherapy.”

**Maviret - glecaprevir / pibrentasvir -
EMA/H/C/004430/II/0024**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Joseph Emmerich, “Submission of the final clinical report from the Phase 3 study M16-126 (A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Adults with Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection).”

**Maviret - glecaprevir / pibrentasvir -
EMA/H/C/004430/II/0025**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Joseph Emmerich, "Update of sections 4.2, 4.8 and 5.1 of the SmPC to shorten the treatment duration in treatment-naïve subjects with compensated cirrhosis and Hepatitis C virus GT1, 2, 4, 5, or 6 infection, from 12 to 8 weeks, based on interim results from study M16-135 (A Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Compensated Cirrhosis). In addition, the marketing authorisation holder took the opportunity to revise the submission date of the final CSR for the hepatocellular carcinoma recurrence study in Annex IID."

**Maviret - glecaprevir / pibrentasvir -
EMA/H/C/004430/II/0026**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Joseph Emmerich, "Update of section 5.1 of the SmPC in order to reflect data from two Asian regional Phase 3 studies: study M15-592 (VOYAGE-1 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults with Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection) and study M15-593 (VOYAGE-2 - An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection)."

**Mylotarg - gemtuzumab ozogamicin -
EMA/H/C/004204/II/0007, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, "Update of sections 4.8 and 5.1 of the SmPC based on safety and efficacy data for paediatric patients with relapsed or refractory AML from a systematic literature review."

**Mylotarg - gemtuzumab ozogamicin -
EMA/H/C/004204/II/0008, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Sinan B.

Sarac, "Update the SmPC Section 4.2 to specify the dose and schedule for the second induction. Furthermore, a statement in SmPC Section 4.2 was added to increase awareness about the actual recommended (maximum) dose of Mylotarg and information regarding traceability added to Section 4.4. In addition, the Marketing authorisation holder (MAH) took the opportunity to include minor editorial changes in sections 4.2, 4.4, 4.8 and 5.2 of the SmPC and to make minor updates to bring the PI in line with the latest QRD template version."

**OPDIVO - nivolumab -
EMA/H/C/003985/11/0065**

Bristol-Myers Squibb Pharma EEIG,
Co-Rapporteur: Paula Boudewina van Hennik,
"Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to update posology and clinical related information based on interim results from Phase 3b/4 Study CA209384 (A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks) and further supported by pharmacometric analyses in subjects with 2L+ NSCLC."

**OPDIVO - nivolumab -
EMA/H/C/003985/11/0069**

Bristol-Myers Squibb Pharma EEIG,
Co-Rapporteur: Paula Boudewina van Hennik,
"Update of sections 4.2, 5.1 and 6.6 of the SmPC in order to introduce a new dosing regimen and schedule for adjuvant treatment of melanoma based on population PK data and Exposure-Response (E-R) Efficacy analysis. The Package leaflet has been updated accordingly."

**Qtern - saxagliptin / dapagliflozin -
EMA/H/C/004057/11/0024**

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Amelia Cupelli,
"Update of sections 4.2, 4.4 and 5.1 of the SmPC with information on the glycaemic efficacy and renal safety of dapagliflozin in patients with Type 2 Diabetes Mellitus and moderate renal impairment (CKD 3A) based on final results from study D1690C00024 (DERIVE) (dapagliflozin), and to reflect a change in renal cut-off value for

saxagliptin. The package leaflet is updated accordingly.

The RMP version 4.1 has also been submitted.

In addition, the MAH took the opportunity to update SmPC sections 2, 4.8, 5.2 and Annex II to include the required excipient information in relation to sodium levels and lactose following the update to the Annex to the European Commission guideline on "Excipients in the labelling and package leaflet of medicinal products for human use", as well as to bring the PI in line with EMA guidance ("Compilation of QRD decisions on stylistic matters in product information", EMA/25090/2002 Rev.18, published 08 December 2017)."

Repatha - evolocumab -

EMA/H/C/003766/II/0035/G

Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, "Update of section 5.1 of the SmPC following completion of studies 20110110 (OSLER) and 20120138 (OSLER-2) listed as a category 3 studies in the RMP; study 20110110 (OSLER) was a multicenter, randomized, controlled, open-label, 5-year extension study to assess the long-term safety and efficacy of Repatha in patients with hyperlipidaemia; study 20120138 (OSLER-2) was a multicenter, randomized, controlled, open-label, 3-year extension study designed to assess the long-term safety and efficacy of Repatha in patients with hypercholesterolemia. This variation is submitted to meet the requirement of MEA 002 (OSLER) and MEA 005 (OSLER-2)."

Shingrix - herpes zoster vaccine

(recombinant, adjuvanted) -

EMA/H/C/004336/II/0016

GlaxoSmithkline Biologicals SA, Rapporteur: Bart Van der Schueren, "Update of section 4.5 of the SmPC in order to update the information related to coadministration based on the final results from studies ZOSTER-035 and ZOSTER-042; these are immunogenicity and safety studies in which Shingrix was co-administered either with Merck's 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23; ZOSTER-035) or with GSK's reduced-antigen-content diphtheria and tetanus toxoids and acellular pertussis (dTpa) vaccine (Boostrix; ZOSTER-042); the Package Leaflet is updated accordingly."

**Shingrix - herpes zoster vaccine
(recombinant, adjuvanted) -
EMA/H/C/004336/II/0017**

GlaxoSmithKline Biologicals SA, Rapporteur: Bart Van der Schueren, "Update of section 4.5 of the SmPC in order to update the information on concomitant administration based on final results from study ZOSTER-048 (REC005); this is an immunogenicity and safety study of Shingrix in subjects previously vaccinated with Zostavax; the Package Leaflet is updated accordingly."

**Tecentriq - atezolizumab -
EMA/H/C/004143/II/0028**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of section 4.8 of the SmPC with new ADRs identified in IMpower132 study. This change is supported by safety data as presented in a drug safety report referring to the IMpower132 safety report (report 1089805) previously submitted to the Agency. The package leaflet is updated accordingly."

**TECFIDERA - dimethyl fumarate -
EMA/H/C/002601/II/0059**

Biogen Netherlands B.V., Rapporteur: Martina Weise, "Update of sections 4.8 and 5.1 of the SmPC in order to add the efficacy and safety information based on final results from study 109MS311, a multicentre extension study to determine the long-term safety and efficacy in paediatric subjects with RRMS (final study report already submitted under P46- 020). The Package Leaflet is updated accordingly."

**Translarna - ataluren -
EMA/H/C/002720/II/0053/G, Orphan**

PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, "C.I.4: Update of section 5.3 of the SmPC in order to update the safety information based on final results Charles River 9001126 Three-month juvenile toxicology and toxicokinetic study planned in neonatal dogs listed as category 3 study in the RMP (MEA-005).
C.I.13 Submission of the final report from study WIL-523008 listed as category 3 study in the RMP (MEA/003). This is a Seven-day tolerability and pharmacokinetic study in neonatal dogs.
C.I.13 Submission of the final report from study WIL-523009 listed as category 3 study in the RMP (MEA/004). This is a One-month juvenile dose

range-finding toxicology and toxicokinetic study planned in neonatal dogs age correlating with dosing in newborn paediatric patients to 2 years of age.

C.I.13 Submission of the final report from study (Charles River 5700755 listed as category 3 study in the RMP (MEA/0024). This is a 28-day investigational toxicology and toxicokinetic study of ataluren in juvenile beagle dogs with an 8-week recovery period – Category 3.”

Tremfya - guselkumab -

EMA/H/C/004271/II/0014

Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics, “Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information based on final results from the phase 3 Eclipse study CNT01959PSO3009, comparing guselkumab (Tremfya) and secukinumab (Cosentyx) for the treatment of moderate to severe plaque psoriasis.”

Xermelo - telotristat ethyl -

EMA/H/C/003937/II/0014, Orphan

Ipsen Pharma, Rapporteur: Martina Weise, “To update sections 4.2 and 5.2 of the SmPC following final results from study LX1606-111; this is a Phase 1, open-label, parallel-group study to evaluate the single-dose pharmacokinetics of Telotristat Ethyl in Male and Female Subjects with Severe Hepatic Impairment and Matched Subjects with Normal Function; the Package Leaflet is updated accordingly.”

PRAC Led

WS1601

Glyxambi-EMA/H/C/003833/WS1601/0022

Jentadueto-EMA/H/C/002279/WS1601/0051

Trajenta-EMA/H/C/002110/WS1601/0038

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Update of sections 4.2 and 5.1 of the Trajenta SmPC, update of sections 4.2, 4.4 and 5.1 of the Jentadueto SmPC and section 5.1 of the Glyxambi SmPC, based on the final results from study 1218.74 (CAROLINA study) listed as a category 3 study in the RMP of Jentadueto and

Trajenta, in order to fulfil Trajenta MEA 008.1 and Jentadueto MEA 001.1; this is a phase III randomized, parallel group, double blind study to evaluate Cardiovascular safety of linagliptin versus glimepiride in patients with type 2 diabetes mellitus at high cardiovascular risk. The Package Leaflet for Trajenta is updated accordingly. The RMP version 13.0 for Jentadueto and Trajenta and version 5.0 for Glyxambi have also been submitted. In addition, the Worksharing applicant (WSA) took the opportunity to make corrections throughout the product information for Glyxambi and Jentadueto and to make corrections to the Bulgarian, French, Swedish translations for Glyxambi.”

WS1627

Eviplera-EMEA/H/C/002312/WS1627/

0099

Odefsey-EMEA/H/C/004156/WS1627/

0042

Gilead Sciences Ireland UC, Lead Rapporteur: Johann Lodewijk Hillege, “Update of section 4.9 of the Eviplera and Odefsey SmPCs in order to remove the recommendation to use oral activated charcoal in the event of an overdose of rilpivirine and replace it with a general guidance to contact poison control. In addition the MAH has taken the opportunity to update the lactose wording in section 4.4 of the SmPC and section 2 of the PL of Eviplera, according to the annex to the EC guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use', as well as update section 5.1 of the Eviplera SmPC to reflect the full waiver for the Eviplera PIP. The MAH has also taken the opportunity to introduce minor administrative updates in the product information for both for Eviplera and Odefsey.”

WS1637

Ebymect-EMEA/H/C/004162/WS1637/

0039

Edistride-EMEA/H/C/004161/WS1637/

0032

Forxiga-EMEA/H/C/002322/WS1637/

0051

Xigduo-EMEA/H/C/002672/WS1637/0050

AstraZeneca AB, Lead Rapporteur: Kristina Dunder, “Update of sections 4.4 (Special warnings and precautions for use) and 4.8 (Undesirable effects) of the SmPC of

dapagliflozin-containing products with respect to the Fournier's gangrene class labelling language, following results from the DECLARE study (a Multicentre, Randomized, Double-Blind, Placebo-Controlled cardiovascular outcome trial in Patients with Type 2 Diabetes). The Package Leaflet is updated accordingly."

B.6.10. CHMP-PRAC assessed procedures

Benlysta - belimumab -

EMA/H/C/002015/II/0067

GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Update of section 5.1 of the SmPC based on final results from study BEL115471/HGS1006-C1112 listed as a category 3 study in the RMP; this is a Phase 3/4, multicenter, randomized, double-blind, placebo-controlled, 52-week study to evaluate the efficacy and safety of belimumab in African-American/Black subjects with systemic lupus erythematosus. The RMP version 31 has also been submitted."

BYETTA - exenatide -

EMA/H/C/000698/II/0069

AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "Submission of a justification for extrapolating exenatide once weekly clinical data (previously assessed for Bydureon) to exenatide twice daily (Byetta) in order to include the latest agreed RMP versions for Bydureon (v30, v31s2 and v32s2) also in the dossier for Byetta. As a consequence, the removal of the important potential risk 'Cardiac Events' is proposed also for Byetta."

Giotrif - afatinib -

EMA/H/C/002280/II/0031

Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, "Update of sections 4.4 and 4.8 of the SmPC in order to add gastrointestinal (GI) perforation as an additional side effect based on summaries of clinical trial and post-marketing safety data. The Package Leaflet and the RMP are updated accordingly. The RMP version 8.0 has been submitted including also the update of the RMP due to transition to the revision 2 template as per pharmacovigilance guidance and taking in consideration the recommendation received

during renewal procedure
EMA/H/C/002280/R/0026. In addition the MAH took the opportunity to correct some typographical errors in the German, Austrian and Spanish PIs, to include a linguistic review comments received from Czech Authority during linguistic review of procedure EMA/H/C/002280/R/0026 in the SmPC and to update the list of the local representatives for Austria in the package leaflet.”

Insuman - insulin human -

EMA/H/C/000201/II/0130

Sanofi-Aventis Deutschland GmbH, Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Jean-Michel Dogné, “Submission of the final report from a completed Phase 3 study, HUBIN-L-05335, listed as a category 3 post-authorisation efficacy / safety study in the RMP. This study covers the evaluation of Insuman Implantable 400 IU/ml in patients with Type 1 diabetes treated with the Medtronic MiniMed Implantable Pump System using Insuplant 400 IU/ml, addressing the Post-Authorisation Measure MEA040.

In this application, the RMP v4.0 combines the updates related to HUBIN-L-05335 study final results and the approval of amended protocol V2 of the ongoing Post Authorization Safety Study HUBIN-C-06380 (MEA/047.4 & MEA/047.5, concerning PRAC decision: EMA/PRAC/256519/2018 dated 17-May-2018; updates are limited to Annex 3 of Part VII).”

Reagila - cariprazine -

EMA/H/C/002770/II/0010

Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, “Submission of in vitro metabolism study report (R188-A15) and consequential update of the Risk Management Plan”

TAGRISO - osimertinib -

EMA/H/C/004124/II/0029

AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2 and 5.2 of the SmPC in order to reflect the outcome of study D5160C00035, an open-label, Phase I study to assess the pharmacokinetics, safety and tolerability of osimertinib following a single oral 80 mg dose to patients with advanced solid

tumours and normal renal function or severe renal impairment. This study was a Category 3 study in the EU-RMP. The RMP version 13 has also been submitted.”

TECFIDERA - dimethyl fumarate -

EMA/H/C/002601/II/0058

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “Submission of CSR of study 109MS310, an open-label study to assess the effects of Tecfidera on lymphocyte subsets in subjects with relapsing remitting multiple sclerosis, listed as category 3 study in the RMP.

The RMP (version 10.1) has been updated as a consequence of the completion of this study. The revised RMP also includes updates to reflect safety information available through to the data lock point of 24 January 2019 and to align with the EU RMP Module V (revision 2.01).”

Tyverb - lapatinib -

EMA/H/C/000795/II/0062

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, “Submission of the final report from study EGF117165/LAP016A2206 listed as an obligation in the Annex II of the Product Information. This is an open-label, phase II study to evaluate biomarkers associated with response to subsequent therapies in subjects with HER2-positive metastatic breast cancer receiving treatment with trastuzumab in combination with lapatinib or chemotherapy.

The Annex II and the RMP are updated to reflect the completion of this study. The RMP version 36.0 has also been submitted to address the PRAC recommendation from the last PSUR review.”

Vemlidy - tenofovir alafenamide -

EMA/H/C/004169/II/0020

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Amelia Cupelli, “Update of sections 4.8 and 5.1 of the SmPC based on safety information from interim results at Week 48 of a phase 3, randomized, double blind study (GS-US-320-4018) conducted to evaluate the efficacy and safety of switching from tenofovir disoproxil fumarate (TDF) 300 mg QD to tenofovir alafenamide (TAF) 25 mg QD in subjects with CHB who are virologically

suppressed, listed as a category 3 study in the RMP; the Package Leaflet is updated accordingly. The RMP version 4.1 has also been submitted.”

Xermelo - telotristat ethyl -

EMA/H/C/003937/II/0015, Orphan

Ipsen Pharma, Rapporteur: Martina Weise, PRAC Rapporteur: Adam Przybylkowski, “To update section 5.1 of the SmPC based on final results from study LX1606.1-302.CS (TELEPATH) listed as a category 3 study in the RMP; this is a multicentre, phase III, long-term extension study to further evaluate the safety and tolerability of telotristat etiprate in patients with carcinoid syndrome (CS). The updated RMP version 4.0 has also been submitted, also updating to GVP Module V (Rev 2).”

B.6.11. PRAC assessed procedures

PRAC Led

Komboglyze - saxagliptin / metformin hydrochloride -

EMA/H/C/002059/II/0046

AstraZeneca AB, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP version 15 in order to implement the revised GVP template Rev.2. As a result, the list of safety concerns has been revised and a number of important identified risks, important potential risks and missing information have been reclassified and have been removed from the RMP.”

PRAC Led

Noxafil - posaconazole -

EMA/H/C/000610/II/0057

Merck Sharp & Dohme B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, “Submission of an updated RMP (version 15.1) in order to bring it in line with the guidance included in Good Pharmacovigilance Practices (GVP) Module V (Rev. 2), with the consequent applicable re-evaluation of some safety concerns. In addition to the above updates, the MAH took the opportunity to include data from the completed clinical trial in paediatric subjects PN097 (the CSR for which was submitted to the Agency in February 2019: P46 029), and update

the due date for submission of the final report for the ongoing post-marketing efficacy trial PN069 (changed from December 2019 to 4th quarter of 2020)."

PRAC Led

Rebetol - ribavirin -

EMA/H/C/000246/II/0086

Merck Sharp & Dohme B.V., PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Joseph Emmerich, "Submission of an updated RMP version 5.1 in order to revise safety concerns for ribavirin based on GVP module V (rev. 2) guidance. In addition, the MAH took the opportunity to revise the safety concerns of ribavirin in light of the current era of IFN free regimen, as requested in a previous PSUSA procedure (EMA/H/C/PSUSA/00010007/201707)."

PRAC Led

Stayveer - bosentan -

EMA/H/C/002644/II/0027

Janssen-Cilag International NV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study AC-052-516, (a category 1 study). This is a non-interventional observational study of the disease characteristics and outcomes of PAH in children and adolescents in real-world clinical settings. The RMP version 10 has also been submitted. The RMP has been updated in line with GVP module 2."

PRAC Led

Tracleer - bosentan -

EMA/H/C/000401/II/0091

Janssen-Cilag International NV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, PRAC-CHMP liaison: Alexandre Moreau, "Submission of the final report from study AC-052-516, (a category 1 study). This is a non-interventional observational study of the disease characteristics and outcomes of PAH in children and adolescents in real-world clinical settings. The RMP version 10 has also been submitted. The RMP has been updated in line with GVP module 2."

PRAC Led

Tremfya - guselkumab -

EMA/H/C/004271/II/0013

Janssen-Cilag International N.V., Rapporteur:
Agnes Gyurasics, PRAC Rapporteur: Brigitte
Keller-Stanislawski, PRAC-CHMP liaison: Jan
Mueller-Berghaus, "Update of RMP to remove
exposure during lactation as missing
information."

PRAC Led

Tysabri - natalizumab -

EMA/H/C/000603/II/0114

Biogen Netherlands B.V., Rapporteur: Jan
Mueller-Berghaus, PRAC Rapporteur: Brigitte
Keller-Stanislawski, PRAC-CHMP liaison: Jan
Mueller-Berghaus, "Update of the RMP (version
25.0) with information related to extended
interval dosing that will be added to the
educational materials. Annex IID of the PI also
reflects the above changes."

B.6.12. CHMP-CAT assessed procedures

Kymriah - tisagenlecleucel -

**EMA/H/C/004090/II/0011, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Rune
Kjeken, CHMP Coordinator: Ingrid Wang

**Spherox - spheroids of human autologous
matrix-associated chondrocytes -**

EMA/H/C/002736/II/0008, ATMP

CO.DON AG, Rapporteur: Lisbeth Barkholt, CHMP
Coordinator: Kristina Dunder

YESCARTA - axicabtagene ciloleucel -

**EMA/H/C/004480/II/0008, Orphan,
ATMP**

Kite Pharma EU B.V., Rapporteur: Jan
Mueller-Berghaus, CHMP Coordinator: Jan
Mueller-Berghaus

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

PRAC Led

Imlygic - talimogene laherparepvec -

EMA/H/C/002771/II/0034, ATMP

Amgen Europe B.V., Rapporteur: Olli Tenhunen,

CHMP Coordinator: Tuomo Lapveteläinen, PRAC
Rapporteur: Brigitte Keller-Stanislawski,
PRAC-CHMP liaison: Jan Mueller-Berghaus, "To
update the RMP for Imlygic to version 7.0 in order
to add 2 category 3 studies (Studies 20180062
and 20180099), as well as an internal evaluation
of managed distribution process metrics, to
evaluate the effectiveness of additional risk
minimization measures (aRMM)."

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS1585

Infanrix

hexa-EMEA/H/C/000296/WS1585/0258

GlaxoSmithkline Biologicals SA, Lead

Rapporteur: Bart Van der Schueren

WS1593

**Ambirix-EMEA/H/C/000426/WS1593/
0098**

**Twinrix Adult-EMEA/H/C/000112/
WS1593/0133**

**Twinrix Paediatric-EMEA/H/C/000129/
WS1593/0134**

GlaxoSmithkline Biologicals SA, Lead

Rapporteur: Bart Van der Schueren

WS1602/G

**Leganto-EMEA/H/C/002380/WS1602/
0030/G**

**Neupro-EMEA/H/C/000626/WS1602/
0084/G**

UCB Pharma S.A., Lead Rapporteur: Bruno
Sepodes

WS1615

**Actraphane-EMEA/H/C/000427/WS1615/
0078**

**Actrapid-EMEA/H/C/000424/WS1615/
0072**

**Insulatard-EMEA/H/C/000441/WS1615/
0075**

**Levemir-EMEA/H/C/000528/WS1615/
0093**

**Mixtard-EMEA/H/C/000428/WS1615/
0079**

**Protaphane-EMEA/H/C/000442/WS1615/
0074**

**Ryzodeg-EMEA/H/C/002499/WS1615/
0032**

Tresiba-EMEA/H/C/002498/WS1615/0038

**Xultophy-EMEA/H/C/002647/WS1615/
0030**

Novo Nordisk A/S, Lead Rapporteur: Sinan B. Sarac

WS1621

**Bexsero-EMEA/H/C/002333/WS1621/
0077**

**Menveo-EMEA/H/C/001095/WS1621/
0087**

GSK Vaccines S.r.l, Lead Rapporteur: Johann Lodewijk Hillege

WS1623

**Hexacima-EMEA/H/C/002702/WS1623/
0091**

**Hexaxim-EMEA/H/W/002495/WS1623/
0096**

**Hexyon-EMEA/H/C/002796/WS1623/
0095**

Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus

WS1626/G

**Glyxambi-EMEA/H/C/003833/WS1626/
0023/G**

**Jardiance-EMEA/H/C/002677/WS1626/
0044/G**

**Synjardy-EMEA/H/C/003770/WS1626/
0040/G**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege

WS1631/G

**Mirapexin-EMEA/H/C/000134/WS1631/
0090/G**

**Sifrol-EMEA/H/C/000133/WS1631/0081/
G**

Boehringer Ingelheim International GmbH, Lead Rapporteur: Mark Ainsworth

WS1633/G

**Blitzima-EMEA/H/C/004723/WS1633/
0026/G**

**Ritemvia-EMEA/H/C/004725/WS1633/
0026/G**

**Truxima-EMEA/H/C/004112/WS1633/
0029/G**

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz, "Update of section 5.1 of the SmPC to reflect the final results of the PRIMA study (MO18264), a study in Patients with Advanced Follicular Lymphoma Evaluating the

Benefit of Maintenance Therapy with Rituximab after Induction of Response with Chemotherapy plus Rituximab in Comparison with No Maintenance Therapy.

The annexes are also updated to comply with the CHMP guideline on excipients regarding the sodium content.

Extension of indication to include the maintenance of remission of polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package leaflet is updated accordingly. In addition, the MAH took the opportunity to implement a terminology change in Annex II.

Extension of indication to include the treatment of patients with moderate to severe pemphigus vulgaris (PV); as a consequence, sections 4.1, 4.2, 4.3, 4.4, 4.8 and 5.1 of the SmPC are updated. Data from a phase III, randomized, controlled, multicenter, open-label study (Study ML22196) evaluating rituximab treatment plus short-term, low dose prednisone treatment compared to long-term, standard dose prednisone treatment as first-line treatment in patients with moderate to severe pemphigus had been provided. The Package leaflet is updated accordingly. Minor corrections are also proposed for the sake of accuracy and clarity. ."

WS1638

Trevicta-EMEA/H/C/004066/WS1638/0023

Xeplion-EMEA/H/C/002105/WS1638/0044

Janssen-Cilag International NV, Lead
Rapporteur: Kristina Dunder

WS1639

Entresto-EMEA/H/C/004062/WS1639/0025

Neparvis-EMEA/H/C/004343/WS1639/0024

Novartis Europharm Limited, Lead Rapporteur:
Johann Lodewijk Hillege

WS1642/G

Rixathon-EMEA/H/C/003903/WS1642/0024/G

Riximyo-EMEA/H/C/004729/WS1642/0024/G

Sandoz GmbH, Lead Rapporteur: Jan

WS1645

Exelon-EMEA/H/C/000169/WS1645/0123

**Prometax-EMEA/H/C/000255/WS1645/
0124**

Novartis Europharm Limited, Lead Rapporteur:
Alexandre Moreau

**Hexacima-EMEA/H/C/002702/WS1624/
0090/G**

**Hexaxim-EMEA/H/W/002495/WS1624/
0095/G**

**Hexyon-EMEA/H/C/002796/WS1624/
0094/G**

Sanofi Pasteur, Lead Rapporteur: Jan
Mueller-Berghaus

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

F.1. Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended

F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. Ongoing procedures

G.3. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.3.1. List of procedures concluding at 26-29 May 2019 CHMP plenary:

Immunology-Rheumatology-Transplantation

- | | | |
|----|---|---|
| 1. | Treatment of Steroid Refractory Gastro-Intestinal predominant acute Graft versus Host Disease (SR-GI-aGvHD) | The CHMP denied eligibility to PRIME and adopted the critical summary report. |
|----|---|---|
-

Cardiovascular diseases

- | | | |
|----|---|---|
| 2. | SME; Reduction/prevention of myocardial necrosis following percutaneous coronary intervention for an acute ST-elevation myocardial infarction | The CHMP denied eligibility to PRIME and adopted the critical summary report. |
|----|---|---|
-

Neurology

- | | | |
|----|---|---|
| 3. | Treatment of motor deficits arising from traumatic brain injury | The CHMP denied eligibility to PRIME and adopted the critical summary report. |
| 4. | Treatment of ataxia telangiectasia | The CHMP denied eligibility to PRIME and adopted the critical summary report. |
-

Oncology

- | | | |
|----|---|--|
| 5. | Allogeneic EBV-specific Cytotoxic T Lymphocytes (Allogeneic EBV-specific CTL); ATMP; Treatment of rituximab refractory Post-Transplant Lymphoproliferative Disorder (PTLD) | The CHMP granted eligibility to PRIME and adopted the critical summary report. |
|----|---|--|
-

G.3.2. List of procedures starting in May 2019 for June 2019 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address